Hormone Profiles

[maxmuscle1]

Old school methyltest. Good article again! Thx

Max

 

[Pcushion]

Old school methyltest. Good article again! Thx

Max

Methyltest is actually just the standard they were comparing Winstrol to. I have a whole write up
on methyltest up next!

- - - Updated - - -

Androgenic 94-130
Anabolic 115-150
Standard Testosterone
Chemical Names 17b-hydroxy-17a-methyl-4-androsten-3-one, 17alpha-methylandrost-4-en-3-one-17b-ol
Estrogenic Activity high
Progestational Activity not significant
​

[h=3]Description:[/h][FONT=&quot]Methyltestosterone is an orally available form of the primary male androgen testosterone. Looking at the structure of this steroid, we see it is basically just testosterone with an added methyl group at the c-17 alpha position (a c-17 alpha alkylated substance), which allows for oral administration. The resultant compound “methylated-testosterone” was among the first functional oral steroids to be produced. This field of research has consequently improved greatly over the years, and today methyltestosterone is quite crude in comparison to many of the other orals that were subsequently developed. The action of this steroid is moderately anabolic and androgenic, with high estrogenic activity due to its aromatization to 17-alpha methyl estradiol. This generally makes methyltestosterone too troublesome (in terms of estrogenic side effects) to use for muscle-building purposes.[/FONT]
[h=3]History:[/h][FONT=&quot]Methyltestosterone was first described in 1935,[SUP]528[/SUP] and was one of the first oral androgens to be used in clinical medicine (it follows Proviron, the first oral androgen, by one year). Its main clinical use at the time of development was as an oral medication to replace testosterone (and its anabolic and/or androgenic activity) in males when endogenous levels were insufficient (Andropause), although the drug was adopted for a number of other uses over the years as well. These include the treatment of cryptorchidism (undescended testicles), breast cancer in postmenopausal women, excessive lactation and breast pain after pregnancy in mothers not nursing, osteoporosis, and, more recently, female menopause (supporting the overall energy and sexual interest of the patient).[/FONT]
[FONT=&quot]In addition to standard tablets and capsules, methyltestosterone has also been commercially prepared in sublingual or buccal tablets. Metandren Linguets from Ciba Pharmaceutical Company were perhaps the most recognized, and were popularly sold from the 1950’s to 1990’s. These tablets were placed under the tongue or between the gum and cheek and left to dissolve, delivering the drug to circulation via the mucous membranes, bypassing the liver. Sublingual or buccal intake approximately doubles the bioavailability of methyltestosterone, and also provides peak levels of drug rapidly (approximately 1 hour after dosing instead of 2 hours). Although Ciba’s Metandren Linguets are no longer commercially available, numerous other sublingual/buccal methyltestosterone tablets are still in production today.[/FONT]
[FONT=&quot]Methyltestosterone remains a controversial steroid. Although it has a long history, and arguably a justifiable safety record, it is no longer widely used, and is even being withdrawn from many drug markets. The German Endocrine Society made an official statement that methyltestosterone was obsolete in 1981, and the drug would be removed from German pharmacies some seven years later. Most European nations followed suit. The drug remains available in the United States, although most clinicians generally find it to be a poor choice and don’t prescribe it. Its potential hepatotoxicity is usually cited as a reason, especially when long-term androgen therapy is contemplated. The one exception seems to be the growing interest in using oral methyltestosterone in low doses to treat female menopause. Early success with Estratest (Solvay) seems to indicate future expansion for this application. Although many markets no longer produce this drug, especially as a single-ingredient product, methyltestosterone remains widely produced in many others.[/FONT]
[h=3]How Supplied:[/h][FONT=&quot]Methyltestosterone is widely available in human drug markets. Composition and dosage may vary by country and manufacturer.[/FONT]
[h=3]

[/h][h=3]Structural Characteristics:[/h][FONT=&quot]Methyltestosterone is a modified form of testosterone. It differs by the addition of a methyl group at carbon 17-alpha, which helps protect the hormone during oral administration. As is typical with c17-alpha alkylation, the resulting steroid has lower anabolic activity than its parent testosterone.[/FONT]
[h=3]Side Effects (Estrogenic):[/h][FONT=&quot]Methyltestosterone is aromatized by the body, and is highly estrogenic due to its conversion to 17-alpha methylestradiol, a synthetic estrogen with high biological activity. 17-alpha methylation actually slows the rate of aromatization, although the potent nature of 17-methylestradiol more than compensates for this. Gynecomastia is often a concern during treatment, and may present itself quite early into a cycle (particularly when higher doses are used). At the same time water retention can become a problem, causing a notable loss of muscle definition as both subcutaneous water retention and fat levels build. To avoid strong estrogenic side effects, it may be necessary to use an anti-estrogen such as Nolvadex®. One may alternately use an aromatase inhibitor like Arimidex® (anastrozole), which is a more effective remedy for estrogen control. Aromatase inhibitors, however, can be quite expensive in comparison to standard estrogen maintenance therapies, and may also have negative effects on blood lipids.[/FONT]
[h=3]Side Effects (Androgenic):[/h][FONT=&quot]Methyltestosterone is classified as an androgen. Androgenic side effects are common with this substance, and may include bouts of oily skin, acne, and body/facial hair growth. Higher doses are more likely to cause such side effects. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Those genetically prone to male pattern hair loss may wish to opt for a milder, less androgenic, anabolic steroid. As a potent androgen, this steroid may also increase aggressiveness. Women are additionally warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Like testosterone, methyltestosterone converts to a more potent steroid via interaction with the 5-alpha reductase enzyme, in this case 17-alpha-methyldihydrotestosterone. The relative androgenicity of methyltestosterone may be reduced, although not completely eliminated, by the concurrent use of finasteride or dutasteride.[/FONT]
[h=3]Side Effects (Hepatotoxicity):[/h][FONT=&quot]Methyltestosterone is a c17-alpha alkylated compound. This alteration protects the drug from deactivation by the liver, allowing a very high percentage of the drug entry into the bloodstream following oral administration. C17-alpha alkylated anabolic/androgenic steroids can be hepatotoxic. Prolonged or high exposure may result in liver damage. In rare instances life-threatening dysfunction may develop. It is advisable to visit a physician periodically during each cycle to monitor liver function and overall health. Intake of c17-alpha alkylated steroids is commonly limited to 6-8 weeks, in an effort to avoid escalating liver strain.[/FONT]
[FONT=&quot]Methyltestosterone was the first oral steroid linked to hepatic damage. This may be, in part, related to the early widespread use of the compound, as the drug generally displays acceptable safety when used in clinically prescribed dosages (serious liver toxicity cannot be completely excluded, however, even at clinical doses). When taken at a dose of 30 mg daily for 5 weeks, hepatotoxicity, as measured by bromosulphalein (BSP) retention, was low in one study.[SUP]529[/SUP] In a separate investigation, a majority of patients noticed significant BSP retention after only 2 weeks of therapy with 67mg daily.[SUP]530[/SUP]Severe liver complications are rare given the periodic nature in which most people use oral anabolic/androgenic steroids, although cannot be excluded with methyltestosterone, especially with high doses and/or prolonged administration periods.[/FONT]
[FONT=&quot]The use of a liver detoxification supplement such as Liver Stabil, Liv-52, or Essentiale Forte is advised while taking any hepatotoxic anabolic/androgenic steroids.[/FONT]
[h=3]Side Effects (Cardiovascular):[/h][FONT=&quot]Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism.[/FONT]
[FONT=&quot]Methyltestosterone has a strong effect on the hepatic management of cholesterol due to its structural resistance to liver breakdown and route of administration. Studies have demonstrated an approximate 35% decrease in HDL cholesterol and a 30% increase in LDL cholesterol with 40 mg per day.[SUP]531[/SUP] These changes occurred within 2-4 weeks of the initiation of therapy, and persisted for 2 weeks after discontinuation of the drug. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.[/FONT]
[FONT=&quot]To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.[/FONT]
[h=3]Side Effects (Testosterone Suppression):[/h][FONT=&quot]All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.[/FONT]
[FONT=&quot]The above side effects are not inclusive. For more detailed discussion of potential side effects, see the Steroid Side Effects section of this book.[/FONT]
[h=3]Administration (General):[/h][FONT=&quot]Studies have shown that taking an oral anabolic steroid with food may decrease its bioavailability.[SUP]532[/SUP] This is caused by the fat-soluble nature of steroid hormones, which can allow some of the drug to dissolve with undigested dietary fat, reducing its absorption from the gastrointestinal tract. For maximum utilization, this steroid should be taken on an empty stomach.[/FONT]
[h=3]Administration (Men):[/h][FONT=&quot]To treat androgen insufficiency, prescribing guidelines call for a daily dosage of 10-40 mg. The dose is reduced by 50% when administered in sublingual or buccal form. The drug would be used for extended periods so long as the patent’s laboratory results (hepatotoxicity, serum lipids, etc.) do not necessitate its discontinuance. When used for physique- or performance-enhancing purposes, a daily dosage of 10-50 mg is most commonly used, taken in cycles lasting no more than 6-8 weeks in length. Methyltestosterone is most commonly used not as an anabolic, but to stimulate aggression in the user. Powerlifters, bodybuilders, and competitive athletes often attempt to harness this effect, looking for extra intensity in a training session or competition. Aside from this, methyltestosterone offers little except side effects. It is quite toxic, elevating liver enzymes and causing acne, gynecomastia, aggression, and water retention quite easily. Were one to tolerate these side effects, methyltestosterone will offer only poor quality (bulky) gains. One should also be prepared for a substantial loss of size and bodyweight at the conclusion of each cycle with methyltestosterone, due to the high level of water excretion once the drug is discontinued (during administration water retention will account for a considerable percentage of the total weight gain).[/FONT]
[h=3]Administration (Women):[/h][FONT=&quot]Methyltestosterone is not widely used with women in clinical medicine. When applied, it is most often used as a secondary medication during inoperable breast cancer, when other therapies have failed to produce a desirable effect. The dosage used for this application can be as high as 200 mg per day. Low doses of methyltestosterone have been used in recent years to treat the symptoms of menopause. An example is the product Estratest, which contains esterified estrogens and 2.5 mg of methyltestosterone. A dosage of 1 tablet per day may improve energy, libido, and overall wellness of the patient, as well as combat osteoporosis (while estrogen replacement may halt calcium loss in the bones, testosterone tends to increase calcium stores). Methyltestosterone is generally not recommended for women for physique- or performance-enhancing purposes due to its strong androgenic nature and tendency to produce virilizing side effects.[/FONT]
[h=3]Availability:[/h][FONT=&quot]Pharmaceutical preparations containing methyltestosterone are fairly limited given the infrequent use of this drug in clinical practice. This drug is also unpopular on the black market, and not widely distributed by underground labs.[/FONT]

 

[Pcushion]

Androgenic: no data available
Anabolic >100
Standard Methyltestosterone (oral)
Chemical Name 4-chloro-17a-methyl-17b-hydroxyandrosta-1,4-dien-3-one
Estrogenic Activity none
Progestational Activity no data available (low)
Description:
Chlorodehydromethyltestosterone, generic name for the more recognized brand Oral Turinabol, is a potent derivative of Dianabol. This oral steroid is structurally a cross between methandrostenolone and clostebol (4-chlorotestosterone), having the same base structure as Dianabol with the added 4-chloro alteration of clostebol. This alteration makes chlorodehydromethyltestosterone a milder cousin of Dianabol, the new steroid displaying no estrogenic and a much less androgenic activity in comparison to its more famous counterpart. The anabolic activity of chlorodehydromethyltestosterone is somewhat lower than that of Dianabol as well, but it does maintain a much more favorable balance of anabolic to androgenic effect. This means that at any given level of muscle-building activity, chlorodehydromethyltestosterone will be less likely to produce androgenic side effects.

History:
Chlorodehydromethyltestosterone was first described in 1962.564 Jenapharm (Jena, Germany) soon after released the drug for sale in the East German prescription drug market, under the brand name Oral Turinabol. The drug was favored by clinicians for its highly anabolic and low anabolic nature, lending itself to use in not only adult males, but women and children as well. The product was manufactured in two strengths, containing 1 mg and 5 mg of drug per tablet, so that a lower-dosed version was available for the more sensitive populations. Chlorodehydromethyltestosterone was applied for a number of medical uses; mainly those focusing on the building or preservation of lean muscle tissue and bone mass.

Oral Turinabol became a steroid of infamy during the 1990’s, when it was revealed that chlorodehydromethyltestosterone had been one of the closely held secrets inside the “East German Doping Machine.” This is referring to the state-sponsored doping program, called “State Plan Research Theme 14.25,” that operated in East Germany between 1974 and 1989. It was an aggressive anabolic steroid administration program, designed with one goal in mind: cheating the Olympic drug test. In many cases, the Olympic athletes, both male and female, were unwitting participants, simply told by their trainers and coaches that they were being given “vitamins.” Many of these blue vitamins turned out to be Oral Turinabol, a potent and undetectable (at the time) anabolic steroid. As many as 10,000 athletes were given anabolic steroids during the time the program was active, many of them taking Oral Turinabol. For a more in-depth look at this dramatic historic event, including the trials of several former East German officials for their participation, I recommend you look at the book “Faust’s Gold: Inside the East German Doping Machine” by Steven Ungerleider.

In spite of an arguably favorable profile of activity and safety record, Jenapharm discontinued Oral Turinabol in 1994. This was at a time when a great deal of negative attention was being given to sports doping, lending credibility to the speculation that this decision was one based on public relations, and not necessarily finances or health concerns over the drug. Regardless, Jenapharm was acquired by Schering AG (Germany) in 1996, a company with no interest in reliving the controversies of the past (Schering had already discontinued many of its controversial anabolic steroid products as well). Before or since, no other brand of chlorodehydromethyltestosterone has existed as a prescription drug product. Today, this agent is still available, but is only produced by a small number of underground manufacturers and export-only suppliers.

How Supplied:
Chlorodehydromethyltestosterone is not available as a prescription drug product. When manufactured, it was found in 1 mg and 5 mg tablets, sold in Germany/German Democratic Republic.


Structural Characteristics:
Chlorodehydromethyltestosterone is a modified form of testosterone. It differs by: 1) the addition of a methyl group at carbon 17-alpha, which helps protect the hormone during oral administration, 2) the introduction of a double bond between carbons 1 and 2 (1-ene), which shifts the anabolic to androgenic ratio in favor of the former, and 3) the attachment of a chloro group at carbon 4, which inhibits steroid aromatization and reduces relative androgenicity.

Side Effects (Estrogenic):
Chlorodehydromethyltestosterone is not aromatized by the body, and is not measurably estrogenic. An anti-estrogen is not necessary when using this steroid, as gynecomastia should not be a concern even among sensitive individuals. Since estrogen is the usual culprit with water retention, this steroid instead produces a lean, quality look to the physique with no fear of excess subcutaneous fluid retention. This makes it a favorable steroid to use during cutting cycles, when water and fat retention are major concerns.

Side Effects (Androgenic):
Although chlorodehydromethyltestosterone is classified as an anabolic steroid, androgenic side effects are still possible with this substance. These may include bouts of oily skin, acne, and body/facial hair growth. Doses higher than normally prescribed are more likely to cause such side effects. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Women are additionally warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Chlorodehydromethyltestosterone is not extensively metabolized by the 5-alpha reductase enzyme, so its relative androgenicity is not greatly altered by the concurrent use of finasteride or dutasteride

Side Effects (Hepatotoxicity):
Chlorodehydromethyltestosterone is a c17-alpha alkylated compound. This alteration protects the drug from deactivation by the liver, allowing a very high percentage of the drug entry into the bloodstream following oral administration. C17-alpha alkylated anabolic/androgenic steroids can be hepatotoxic. Prolonged or high exposure may result in liver damage. In rare instances life-threatening dysfunction may develop. It is advisable to visit a physician periodically during each cycle to monitor liver function and overall health. Intake of c17-alpha alkylated steroids is commonly limited to 6-8 weeks, in an effort to avoid escalating liver strain. The use of a liver detoxification supplement such as Liver Stabil, Liv-52, or Essentiale Forte is advised while taking any hepatotoxic anabolic/androgenic steroids.

Side Effects (Cardiovascular):
Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Chlorodehydromethyltestosterone has a strong effect on the hepatic management of cholesterol due to its non-aromatizable nature, structural resistance to liver breakdown, and route of administration. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.

To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.

Side Effects (Testosterone Suppression):
All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.

The above side effects are not inclusive. For more detailed discussion of potential side effects, see the Steroid Side Effects section of this book.

Administration (General):
Studies have shown that taking an oral anabolic steroid with food may decrease its bioavailability.565 This is caused by the fat-soluble nature of steroid hormones, which can allow some of the drug to dissolve with undigested dietary fat, reducing its absorption from the gastrointestinal tract. For maximum utilization, this steroid should be taken on an empty stomach.

Administration (Men):
A common clinical dose of Oral Turinabol is estimated to be 5 mg per day; actual prescribing guidelines are unavailable. In the athletic arena, an effective oral daily dosage falls in the range of 15-40 mg, taken in cycles lasting no more than 6-8 weeks to minimize hepatotoxicity. This level is sufficient for measurable increases in lean muscle mass and strength. This agent is most often applied as a pre-contest or cutting steroid for bodybuilding purposes, and is not viewed as an ideal bulking agent due to its lack of estrogenicity. Athletes in sports where speed tends to be a primary focus also find strong favor in chlorodehydromethyltestosterone, obtaining a strong anabolic benefit without having to carry around any extra water or fat weight.

Administration (Women):
A common clinical dose of Oral Turinabol is estimated to be 1-2.5 mg per day; actual prescribing guidelines are unavailable. In the athletic arena, women would commonly take a single 5 mg tablet per day, taken in cycles lasting no more than 4-6 weeks to minimize hepatotoxicity. Virilizing effects are unlikely at this level of use. Much higher doses were often used with female athletes in the former GDR doping program, but often to detriment of strong virilizing side effects.

Availability:
Oral Turinabol has been unavailable as a prescription drug product in Germany (the sole country of manufacture for most of its history) since 1994. A very small number of pharmaceutical companies have marketed the drug since, mainly in less regulated markets of Eastern Europe and Asia, where black market demand still influences production.

 

[maxmuscle1]

Nice ! Always good articles. Keep em going!

Max

 

[Pcushion]

Androgenic 37
Anabolic 125
Standard Testosterone
Chemical Names 19-norandrost-4-en-3-one-17beta-ol, 17beta-hydroxy-estr-4-en-3-one
Estrogenic Activity low
Progestational Activity moderate
Description:
Durabolin is a trade name for nandrolone phenylpropionate, an injectable form of the anabolic steroid nandrolone. The properties of this drug are strikingly similar to those of Deca-Durabolin®, which uses the slower acting drug nandrolone decanoate. The primary difference between these two preparations is the speed in which nandrolone is released into the blood. While nandrolone decanoate provides a release of nandrolone from the area of injection lasting approximately 3 weeks, nandrolone phenylpropionate is active for only about a week. In clinical situations, Deca-Durabolin can thus be injected once every 2 or 3 weeks, while Durabolin® is usually administered every several days to once weekly. Otherwise, the two drugs are virtually interchangeable. Like Deca-Durabolin, Durabolin is valued by athletes and bodybuilders for its abilities to promote strength and lean muscle mass gains without significant estrogenic or androgenic side effects.
History:
Nandrolone phenylpropionate was first described in 1957.471 It became a prescription medication shortly after, sold by the international pharmaceuticals giant Organon (now Merck/MSD) under the brand name Durabolin. When first introduced to the United States, indicated uses of nandrolone phenylpropionate included pre- and postoperative lean mass retention, osteoporosis, advanced breast cancer, weight loss due to convalescence or disease, geriatric states (general weakness and frailty), burns, severe trauma, ulcers, adjunct therapy with certain forms of anemia, and selective cases of growth and development retardation in children. During the 1970’s, the FDA began revising the indicated uses of this drug, however, and they were soon significantly narrowed. Moving forward, the drug was mainly being indicated for the treatment of advanced metastatic breast cancer, and as adjunct therapy for the treatment of senile and post-menopausal osteoporosis.
Durabolin was a key focus of Organon’s marketing efforts only for well less than a decade following its release. Once Deca-Durabolin was introduced during the 1960’s, this shorter-acting counterpart, although still available, started to take a back seat. Durabolin was not completely abandoned by Organon at the time, however, partly due to the fact that it was given a slightly different set of therapeutic uses in certain countries, and therefore continued to hold onto a niche market for some time. As the size of the anabolic steroid market continued to grow throughout the 1970’s and ’80’s, it was nandrolone decanoate that was attracting the most attention of other drug manufacturers. Numerous drug companies had produced their own versions of nandrolone phenylpropionate over the years, however. Today, the drug remains scarcely available. It is unknown if the present owner of Organon (Merck/MSD) will market Durabolin, or if its production (as a brand name product) has ended.
How Supplied:
Nandrolone phenylpropionate is available in select human drug markets. Composition and dosage may vary by country and manufacturer, but usually contain 25 mg/mL or 50 mg/mL of steroid dissolved in oil.

Structural Characteristics:
Nandrolone phenylpropionate is a modified form of nandrolone, where a carboxylic acid ester (propionic phenyl ester) has been attached to the 17-beta hydroxyl group. Esterified steroids are less polar than free steroids, and are absorbed more slowly from the area of injection. Once in the bloodstream, the ester is removed to yield free (active) nandrolone. Esterified steroids are designed to prolong the window of therapeutic effect following administration, allowing for a less frequent injection schedule compared to injections of free (unesterified) steroid. Nandrolone phenylpropionate provides a sharp spike in nandrolone release 24-48 hours following deep intramuscular injection, and declines to near baseline levels within a week.
Side Effects (Estrogenic):
Nandrolone has a low tendency for estrogen conversion, estimated to be only about 20% of that seen with testosterone.472 This is because while the liver can convert nandrolone to estradiol, in other more active sites of steroid aromatization such as adipose tissue nandrolone is far less open to this process.473 Consequently, estrogen- related side effects are a much lower concern with this drug than with testosterone. Elevated estrogen levels may still be noticed with higher dosing, however, and may cause side effects such as increased water retention, body fat gain, and gynecomastia. An anti-estrogen such as clomiphene citrate or tamoxifen citrate may be necessary to prevent estrogenic side effects if they occur. One may alternately use an aromatase inhibitor like Arimidex® (anastrozole), which more efficiently controls estrogen by preventing its synthesis. Aromatase inhibitors can be quite expensive in comparison to anti-estrogens, however, and may also have negative effects on blood lipids.
It is of note that nandrolone has some activity as a progestin in the body.474 Although progesterone is a c-19 steroid, removal of this group as in 19-norprogesterone creates a hormone with greater binding affinity for its corresponding receptor. Sharing this trait, many 19-nor anabolic steroids are shown to have some affinity for the progesterone receptor as well.475 The side effects associated with progesterone are similar to those of estrogen, including negative feedback inhibition of testosterone production and enhanced rate of fat storage. Progestins also augment the stimulatory effect of estrogens on mammary tissue growth. There appears to be a strong synergy between these two hormones here, such that gynecomastia might even occur with the help of progestins, without excessive estrogen levels. The use of an anti-estrogen, which inhibits the estrogenic component of this disorder, is often sufficient to mitigate gynecomastia caused by nandrolone.
Side Effects (Androgenic):
Although classified as an anabolic steroid, androgenic side effects are still possible with this substance, especially with higher doses. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Women are warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Nandrolone is a steroid with relatively low androgenic activity relative to its tissue-building actions, making the threshold for strong androgenic side effects comparably higher than with more androgenic agents such as testosterone, methandrostenolone, or fluoxymesterone. It is also important to point out that due to its mild androgenic nature and ability to suppress endogenous testosterone, nandrolone is prone to interfering with libido in males when used without another androgen.
Note that in androgen-responsive target tissues such as the skin, scalp, and prostate, the relative androgenicity of nandrolone is reduced by its reduction to dihydronandrolone (DHN).476 477
The 5-alpha reductase enzyme is responsible for this metabolism of nandrolone. The concurrent use of a 5-alpha reductase inhibitor such as finasteride or dutasteride will interfere with site-specific reduction of nandrolone action, considerably increasing the tendency of nandrolone to produce androgenic side effects. Reductase inhibitors should be avoided with nandrolone if low androgenicity is desired.
Side Effects (Hepatotoxicity):
Nandrolone is not c-17 alpha alkylated, and not known to have hepatotoxic effects. Liver toxicity is unlikely.
Side Effects (Cardiovascular):
Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Studies administering 600 mg of nandrolone decanoate per week for 10 weeks demonstrated a 26% reduction in HDL cholesterol levels.478 This suppression is slightly greater than that reported with an equal dose of testosterone enanthate, and is in agreement with earlier studies showing a slightly stronger negative impact on HDL/LDL ratio with nandrolone decanoate as compared to testosterone cypionate.479 Nandrolone should still have a significantly weaker impact on serum lipids than c-17 alpha alkylated agents. Anabolic/androgenic steroids may also adversely effect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.
To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.
Side Effects (Testosterone Suppression):
All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Studies administering 100 mg injection of nandrolone phenylpropionate demonstrated a rapid suppression of serum testosterone following a single injection. Testosterone levels declined to approximately 30% of initial level by day 3 after drug administration, and stayed suppressed for approximately 13 days. Regular use is expected to significantly lengthen the endogenous hormone recovery window. It is believed that the progestational activity of nandrolone notably contributes to the suppression of testosterone synthesis during therapy, which can be marked in spite of a low tendency for estrogen conversion.480 Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 2-6 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.
The above side effects are not inclusive. For more detailed discussion of potential side effects, see the Steroid Side Effects section of this book.
Administration (Men):
For general anabolic effects, early prescribing guidelines recommend a dosage of 25-50 mg per week for 12 weeks. The usual dosage for physique- or performance-enhancing purposes is in the range of 200-400 mg per week, taken in cycles 8 to 12 weeks in length. This level is sufficient for most users to notice measurable gains in lean muscle mass and strength. Note that due to the fastacting nature of the phenylpropionate ester, the weekly dosage is usually subdivided into 2 separate applications spaced evenly apart.
Administration (Women):
For general anabolic effects, early prescribing guidelines recommend a dosage of 25-50 mg per week for 12 weeks. When used for physique- or performance-enhancing purposes, a dosage of 50 mg per week (given in a single weekly injection) is most common, taken for cycle lasting 4 to 6 weeks. Higher doses or longer durations of use are discouraged due to potential for androgenic side effects. Although only slightly androgenic, women are occasionally confronted with virilization symptoms when taking this compound. Should virilizing side effects become a concern, nandrolone phenylpropionate should be discontinued immediately to help prevent a permanent appearance.
Availability:
Nandrolone phenylpropionate has declined extensively as a pharmaceutical product. Given its short action, and the limited use of its longer-acting cousin nandrolone decanoate in clinical medicine, there are very few (if any) unique applications remaining for this drug. Thus, there is little justification for its continued production.
Brand name Durabolin appears to be unavailable in all markets worldwide. A small number of generic and brand name products remain in less regulated markets (mainly in Asia), due to continued demand by athletes and bodybuilders.

 

[maxmuscle1]

Appreciate the article as usual. Thanks

Max

 

[Pcushion]

No problem sorry for the delay.

 

[fatballjr]

Clicked just too see the siracha shirt.

 

[maxmuscle1]

Clicked just too see the siracha shirt.

That’s real! Lol

Max

 

[Pcushion]

So I am going to swap things up a little bit. This next hormone is more of an “exotic” it’s claim to fame came from all the old pro hormones that were called tren or claimed to convert to tren. The original ones were precursors to this hormone.

DIENOLONE
(none) 4,9-estradienolone
Formula: Cl8H2402 MW:272
Dienolone is the unmethylated version of Methyldienolone, which was available as a prosteroid before the ban. This steroid is a 9-dehydro derivative of nandrolone and is similar to trenbolone but lacks its double bond at C-I I. The binding affinities for this compound show it to bind to the androgen receptor with slightly less affinity than nandrolone but still stronger than testosterone with similar affinity for the progesterone receptor as nandrolone In fact, this compound has almost
identical binding to nandrolone. Unlike nandrolone, this compound would not be converted to estrogen but may be converted to some degree by 5-alpha reductase to less potent metabolites, similar to nandrolone. This is evident in its low androgenic activity. This molecule would have poor oral activity and would need to be used transdermally or esterified and injected. The anabolic to androgenic ratio for this compound is very favorable with low androgenicity and high anabolic
activity and is slightly misleading because the standard utilized was methyltestosterone. Like
nandrolone, this steroid has been shown to have mixed agonist/antagonist activity for the
progesterone receptor which will contribute to significant shutdown of natural testosterone and may
result in gynecomastia through upregulation of estrogen receptors in the breast and hypothalamus. Ultimately, this steroid would likely perform similarly to nandrolone with less estrogenic and slightly more androgenic activity overall.

AR affinity 134
PR affinity 17
GR affinity 5
SHBG affinity medium
AA ratio 100/10
Estrogen conversion- none

 

[Pcushion]

Androgenic: 850
Anabolic 1,900
Standard Methyltestosterone (oral)
Chemical Names 9a-fluoro-11b,17b-dihydroxy-17a-methyl-4-androsten-3-one, 9a-fluoro-11b-hydroxy-17a-methyltestosterone
Estrogenic Activity none
Progestational Activity no data available (low)
Description:
Fluoxymesterone is an oral anabolic steroid derived from testosterone. More specifically, it is a methyltestosterone derivative, differing by the addition of 11-beta-hydroxy and 9-alpha-fluoro groups. The result is a potent orally active non-aromatizable steroid that exhibits extremely strong androgenic properties. Fluoxymesterone is considerably more androgenic than testosterone, while at the same time the anabolic effects of this agent are considered to be moderate in comparison. This makes fluoxymesterone a great strength drug, but not the most ideal agent for gaining muscle mass. The predominant effects seen when taking fluoxymesterone are increased strength, increased muscle density, and increased definition, with only modest size increases.

History:
Fluoxymesterone was first described in 1956.509 It was assayed that same year, and shown to possess approximately 20 times the anabolic potency of methyltestosterone510 (its relative anabolic effect in humans would not be quite as strong in comparison). It was introduced to the U.S. prescription drug market shortly after under the brand name Halotestin (Upjohn), and soon after that as Ultandren (Ciba). The drug was initially described as halogenated derivative of testosterone, possessing up to 5 times greater anabolic and androgenic potency than methyltestosterone. Early prescribing guidelines recommended its use in both sexes for the promotion of lean tissue repair and growth following such conditions as burns, delayed healing of fractures, chronic malnutrition, debilitating diseases, convalescence, paraplegia, and catabolism induced by long-term administration of cortisone. It was also used in males to treat insufficient androgen levels, and in women to treat abnormal bleeding in the uterus and advanced breast cancer.

By the mid-1970’s, the FDA had been granted much more control over the U.S. drug market. One of the first major changes with steroid medicine came when the FDA required strong substantiation for each potential use of a drug. The prescribing guidelines for fluoxymesterone were soon refined to state that the drug was “effective” for treating various forms of androgen deficiency in males, and reducing the severity of postpartum breast pain and treating androgen-responsive inoperable breast cancer in females. It was also listed as “probably effective” in treating postmenopausal osteoporosis. Current prescribing guidelines for fluoxymesterone list only the uses of treating androgen deficiency in males and breast cancer in females.

In recent years, fluoxymesterone has become viewed more and more as a controversial medication in the eyes of most clinicians. Its hepatotoxicity and potential negative impact of lipids and cardiovascular risk factors are often cited as reasons for avoiding the use of this agent in otherwise healthy males for treating androgen insufficiency. Today, testosterone preparations (injections, gels, patches, implants, etc.) are preferred for this purpose, and they supplement the same androgens missing from the body (testosterone, DHT), not more toxic synthetic derivatives. Fluoxymesterone remains for sale in the U.S. as a generic drug only. It remains available in only limited supply outside of the United States.

How Supplied:
Fluoxymesterone is available in select human drug markets. Composition and dosage may vary by country and manufacturer,although generally contain 2mg, 2.5 mg, 5 mg, or 10 mg per tablet.

halotestin-fluoxymesterone-structure-molecule
Structural Characteristics:
Fluoxymesterone is a modified form of testosterone. It differs by 1) the addition of a methyl group at carbon 17-alpha, which helps protect the hormone during oral administration, 2) the introduction of a fluoro group at carbon 9 (alpha) and 3) the attachment of a hydroxyl group at carbon 11 (beta), which inhibits steroid aromatization. The latter two modifications also greatly enhance the androgenic and relative biological activity of the steroid over 17-alpha methyltestosterone.

Side Effects (Estrogenic):
Fluoxymesterone is not aromatized by the body, and is not measurably estrogenic. An anti-estrogen is not necessary when using this steroid, as gynecomastia should not be a concern even among sensitive individuals. Since estrogen is the usual culprit with water retention, this steroid instead produces a lean, quality look to the physique with no fear of excess subcutaneous fluid retention. This makes it a favorable steroid to use during cutting cycles, when water and fat retention are major concerns.

Side Effects (Androgenic):
Fluoxymesterone is classified as an androgen. Androgenic side effects are common with this substance, and may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Those genetically prone to male pattern hair loss may wish to opt for a milder, less androgenic, anabolic steroid. As a potent androgen, this steroid may also increase aggressiveness. Women are additionally warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement.

Fluoxymesterone appears to be a good substrate for the 5-alpha reductase enzyme. This is evidenced by the fact that a large number of its metabolites are found to be 5-alpha reduced androgens,511 which coupled with its outward androgenic nature, suggests that this steroid is converting to a much more active steroid in androgen responsive target tissues such as the skin, scalp and prostate. It may be possible to reduce the relative androgenicity of fluoxymesterone by the concurrent use of finasteride or dutasteride.

It is also of note that Halotestin has been shown to possess usual androgenic properties. In human studies published back in 1961, the steroid displayed a much stronger tendency to promote phallic enlargement compared to other androgenic effects such as hair growth, libido, and changes in vocal pitch.512 Fluoxymesterone was offering a somewhat different androgenic profile compared to testosterone, and as such demonstrated that it was possible, at some level, to actually tailor drug effect within the broad category of androgenic action. Fluoxymesterone remains considered an androgen, but studies like the above suggest that it may not offer a complete biological equivalent to testosterone where androgenicity is concerned.

Side Effects (Hepatotoxicity):
Fluoxymesterone is a c17-alpha alkylated compound. This alteration protects the drug from deactivation by the liver, allowing a very high percentage of the drug entry into the bloodstream following oral administration. C17-alpha alkylated anabolic/androgenic steroids can be hepatotoxic. Prolonged or high exposure may result in liver damage. In rare instances life-threatening dysfunction may develop. It is advisable to visit a physician periodically during each cycle to monitor liver function and overall health. Intake of c17-alpha alkylated steroids is commonly limited to 6-8 weeks, in an effort to avoid escalating liver strain. Studies administering 20 mg of fluoxymesterone to a group of nine male subjects for two weeks resulted in most patients (6/9) noticing abnormal sulfobromophthalein (BSP) retention,513 a marker of liver stress.

The use of a liver detoxification supplement such as Liver Stabil, Liv-52, or Essentiale Forte is advised while taking any hepatotoxic anabolic/androgenic steroids.

Side Effects (Cardiovascular):
Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Fluoxymesterone has a strong effect on the hepatic management of cholesterol due to its structural resistance to liver breakdown and route of administration. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.

To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.

Side Effects (Testosterone Suppression):
All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.

Studies administering 10 mg, 20 mg, or 30 mg of fluoxymesterone to nine healthy male subjects for up to 12 weeks have demonstrated the strong suppression of endogenous testosterone levels, with inconsistent effects on gonadotropin levels. Although not fully understood, fluoxymesterone is proposed to have a direct suppressive effect on testicular steroidogenesis that is not mediated by the suppression gonadotropins.514
The above side effects are not inclusive. For more detailed discussion of potential side effects, see the Steroid Side Effects page.

Administration (General):
Studies have shown that taking an oral anabolic steroid with food may decrease its bioavailability.515 This is caused by the fat-soluble nature of steroid hormones, which can allow some of the drug to dissolve with undigested dietary fat, reducing its absorption from the gastrointestinal tract. For maximum utilization, this steroid should be taken on an empty stomach.

Administration (Men):
To treat androgen insufficiency, early prescribing guidelines for Halotestin called for a dose of 2-10 mg per day. Modern prescribing guidelines call for a daily dosage of 5-20 mg. Therapy is usually initiated at the full 20 mg dosage,which is later adjusted downward to meet the individual needs of the patient. The drug would be continued long-term unless laboratory tests (lipids, liver enzymes, etc.) or side effects contraindicate its continued use. For physique- or performance-enhancing purposes, an effective oral daily dosage would fall in the range of 10-40 mg, taken in cycles lasting no more than 6-8 weeks to minimize hepatotoxicity. This level is sufficient for measurable increases in muscle strength, which may be accompanied by modest increases in lean muscle mass.

Halotestin is commonly used by athletes in weight-restricted sports like wrestling, powerlifting, and boxing, due to the fact that strength gained from the drug is usually not accompanied by great increases in bodyweight. When properly used, it can allow a competitor to stay within a specified weight range, yet drastically improve his performance. Fluoxymesterone is also commonly used for bodybuilding contest preparation. When the competitor has an acceptably low body fat percentage, the strong androgen level (in absence of excess estrogen) can elicit an extremely hard and defined (“ripped”) look to the muscles. The shift in androgen/estrogen ratio additionally seems to bring about a state in which the body may be more inclined to burn off excess fat and prevent new fat storage. The “hardening” effect of fluoxymesterone would, therefore, be somewhat similar to that seen with trenbolone, although it will be without the same level of mass gain.

In cutting phases, a milder anabolic such as Deca-Durabolin® or Equipoise® is commonly stacked with fluoxymesterone, as they provide good anabolic effect without excessive estrogen buildup. Here, fluoxymesterone provides a well-needed androgenic component, helping to promote a more solid and defined gain in muscle mass, with less interference with energy and libido, than might be obtained with a primarily anabolic agent alone. Perhaps Primobolan®-Depot would be an even better choice, as with such a combination there is no buildup of estrogen, and likewise even less worry of water and fat retention. For mass, one might alternately use an injectable testosterone. A mix of 400 mg per week of testosterone enanthate and 20-30 mg daily of fluoxymesterone, for example, often provides exceptional increases in strength and lean muscle mass. A more significant level of androgenic side effects usually accompanies such a combination, however, as both compounds exhibit strong androgenic activity in the body.

Administration (Women):
Halotestin is most often used as a secondary medication during inoperable androgen-sensitive breast cancer, when other therapies have failed to produce a desirable effect. The dosage used for this application is 10-40 mg per day. Virilizing effects are common at doses of only 10-15 mg per day in these patients. Fluoxymesterone is not recommended for women for physique- or performance-enhancing purposes due to its strong androgenic nature and tendency to produce virilizing side effects.

Availability:
Pharmaceutical preparations containing fluoxymesterone remain scarce. The drug has largely associated with western medical markets, where it has been falling out of favor for most clinical application. The bulk of the supply presently comes from underground steroid manufacturers.

 

[maxmuscle1]

Enjoyed! Thanks again

Max

 

[Oldman85]

I don't see myself ever using Halo, but its an interesting read.

 

[Pcushion]

I don't see myself ever using Halo, but its an interesting read.

Me either. It’s a contest prep drug. 2-3 weeks before show time adds a nice touch. I will say it’s fascinating that it’s suppression on endogenous testosterone is seen at the testicular level and not the the hypothalamus. I believe this trait is unique to this one steroid.

 

[Pcushion]

This Pro hormone brought Mark McGuire a head headache.

ANDROSTENEDIONE
(none) 4-androsten-3, 17-dione
o
Formula: Cl9Hz60z MW: 286
Androstenedione, known popularly as Andro, was the first "prohormone" to be put on the market. It
has little androgen receptor binding affinity and undergoes conversion to testosterone via 17BHSD.
Androstenedione is normally produced by the testes and adrenals at a rate of about 3.2 mg/day and
circulates at a concentration of about 5.4 nmol/L • Of this, only about 7.5% circulates in a free,
unbound state with 6.6% bound to SH BG and 85% bound to albumin. Only about 7% of the androstenedione produced in the body is converted to testosterone while 1.7% is converted to
estrone • Estrone is a weaker estrogen than estradiol, but can be directly converted to estradiol as
well. Soon after it was put onto the market, people began to realize that androstenedione was not very anabolic and tended to produce unwanted side effects (such as gynecomastia) quite easily most likely due to its high affinity for albumin and the fact that high doses were necessary to see any anabolic effect. Androstenedione is known to be a fairly potent aromatase inhibitor but either because it was metabolized quickly or some other reason; it still produced significant estrogenic side effects. Andro could be metabolized to more potent androgenic 5-alpha reduced metabolites and as such, could produce side effects such as acne, hair loss, prostate enlargement and others. Andro was targeted by the media after Mark Macguire admitted to using it during the time when he broke the home-run record. Andro was removed from the market as a consequence of this attention but other products were quickly produced to fill the vacuum. It has been theorized that one could use androstenedione with testosterone to interfere with 17-beta hydroxysteroid dehydrogenase to to decrease the metabolism oftestosterone.ANABOLIC PHARMACOLOGY

 

[Pcushion]

FURAZABOL
(Miotilan~
17a-Methyl-5a-androstano(2,3-c]-( I,2,5]oxadiazol-17p-ol
H
Formula: C2oH30N202 MW: 330
Furazabol is a DHT derivative with an additional ring, similar in structure to stanozolol. This steroid
cannot convert to estrogen and is already 5-alpha reduced so it cannot be reduced further. Furazabol
is reported to have much effect on HPGA. Furazabol does not appear to undergo ring opening
metabolism like danazol. Unlike stanozolol, furazabol seems to have a fairly short half-life of only
J02
This steroid was actually used to lower cholesterol. Androgens reduce HDL cholesterol without having much effect on LDL. This can result in a decrease in total cholesterol but we now know that HDL cholesterol is "good" in the sense that it protects the heart while LDL cholesterol is "bad". Therefore, even though total cholesterol may be reduced, there is actually an increase in cardiovascular risk with these kinds ofchanges. Furazabol is C-17 alpha alkylated, so it will have some potential for liver toxicity. Furazabol is available on the black market, but most people report little muscular gain with this steroid. This is one of those steroids that seems to have gained popularity in its absence. It was always difficult to find because it was only made in Japan and rarely found its way to the black market. It hasn't been available for some time in Japan so it took on a mythical quality because so few had actually used it. It is now available on the black market and users are corning face to face with the fact that this steroid is not very effective. It has a fairly good anabolic to androgenic ratio but it just doesn't seem to deliver significant results in real world use. Perhaps it is due to the half-life or perhaps larger doses are needed to elicit an anabolic response.

 

[Pcushion]

Androgenic 30-60
Anabolic 20-60
Standard Testosterone propionate
Chemical Name 17-alpha-methylandrost-5-ene-3,17-beta-diol
Estrogenic Activity low to moderate
Progestational Activity no data available (low)
​

[h=3]Description:[/h][FONT=&quot]Methylandrostenediol (methandriol for short) is an anabolic steroid derived from dihydrotestosterone. The drug itself is manufactured in two very distinct forms. The first is unesterified (straight) methylandrostenediol, which is used when making an oral medication with this steroid (although an injectable once existed in the U.S.). It is also found as esterified methylandrostenediol dipropionate, which is prepared as an injectable. The added propionate esters in the injectable form extend the activity of the drug for several days. Basically, methandriol drugs are altered c17-alkylated forms of 5-androstenediol. Methandriol is classified as a weak anabolic with weak androgenic properties. It also seems to display some level of estrogenic activity, making this steroid less ideal for dieting. The drug is generally considered too mild, and is not widely popular among bodybuilders and athletes. Sometimes, however, it is used in place of other anabolic/androgenic agents in bulking stacks when available.[/FONT]
[h=3]History:[/h][FONT=&quot]Methandriol was first described in 1935,[SUP]533[/SUP]making this a very old agent as far as synthetic anabolic steroids are concerned. Methylandrostendiol was developed into a medicine by Organon, which sold it in the United States under the Stenediol brand name in both oral (methylandrostenediol) and injectable (methylandrostendiol dipropionate) forms. Many other generics and other brands of methylandrostenediol soon followed, and the drug was a popular anabolic agent in the United States during the 1950’s. Methandriol was essentially the first steroid perceived to have a notable separation of anabolic (higher) and androgenic (lower) effect, a persistent goal of pharmaceutical developers. Early product literature described it as, “a steroid which has considerable of the male hormone’s tissue-building action without to the same extent causing virilization.”[SUP]534[/SUP] It was indicated for use as a, “tissue-builder in cases of retarded growth or failure to gain weight accompanied by protein wastage, negative nitrogen balance, or failure to build body proteins.”[/FONT]
[FONT=&quot]Early assessments of methandriol being primarily anabolic in nature did not hold up well with later extensive use in humans. It was eventually determined that in doses sufficient to promote weight gain, its anabolic properties were accompanied by significant androgenic activity. Ultimately, this drug would be viewed as one of balanced anabolic and androgenic action, not as a highly anabolic agent as originally thought. Organon would go on to develop more effective anabolic agents, such as their 19-nor series of drugs including Durabolin, Deca-Durabolin, and Maxibolin, and eventually discontinued the Stenediol products. The other U.S. brand and generic forms of the drug would follow as well, although methylandrostenediol would persist in the U.S. scene for some time. Currently, no domestic source of the drug exists, although it is still found in certain international markets. It seems most prominent in Australia at the present time, where it remains included in a number of veterinary anabolic steroid products.[/FONT]
[h=3]How Supplied:[/h][FONT=&quot]Methandriol is available in select human and veterinary drug markets. Composition and dosage may vary by country and manufacturer.[/FONT]
[h=3]

[/h][h=3]Structural Characteristics:[/h][FONT=&quot]Methylandrostendiol is a modified form of dihydrotestosterone. It differs by: 1) the addition of a methyl group at carbon 17-alpha to protect the hormone during oral administration and 2) the introduction of a double bond between carbons 5 and 6, which seems to increase the anabolic strength of the steroid (partly by making it resistant to metabolism by 3-hydroxysteroid dehydrogenase in skeletal muscle tissue). Methylandrostenediol dipropionate contains methylandrostenediol modified with the addition of 2 carboxylic acid esters (propionic acid) at the 3-beta and 17-beta hydroxyl groups, which delay the release of free methylandrostenediol from the site of injection (depot).[/FONT]
[h=3]Side Effects (Estrogenic):[/h][FONT=&quot]Methandriol is not directly aromatized by the body, although one of its known metabolites is methyltestosterone, which can aromatize. Methlyandrostenediol is also believed to have some inherent estrogenic activity. It is, likewise, considered a weakly to moderately estrogenic steroid. Gynecomastia is possible during treatment, but generally only when higher doses are used. Water and fat retention can also become issues, again depending on dose. Sensitive individuals may need to addition an anti-estrogen such as Nolvadex® to minimize related side effects.[/FONT]
[h=3]Side Effects (Androgenic):[/h][FONT=&quot]Although often classified as an anabolic steroid, methylandrostenediol is sufficiently androgenic. Androgenic side effects are common with this substance. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Women are warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Note that methylandrostenediol is not affected by 5-alpha reductase, so the relative androgenicity of this steroid is not affected by the concurrent use of finasteride or dutasteride.[/FONT]
[h=3]Side Effects (Hepatotoxicity):[/h][FONT=&quot]Methandriol is a c17-alpha alkylated compound. This alteration protects the drug from deactivation by the liver, allowing a very high percentage of the drug entry into the bloodstream following oral administration. C17-alpha alkylated anabolic/androgenic steroids can be hepatotoxic. Prolonged or high exposure may result in liver damage. In rare instances life-threatening dysfunction may develop. It is advisable to visit a physician periodically during each cycle to monitor liver function and overall health. Intake of c17-alpha alkylated steroids is commonly limited to 6-8 weeks, in an effort to avoid escalating liver strain. Injectable forms of the drug may present slightly less strain on the liver by avoiding the first pass metabolism of oral dosing, although may still present substantial hepatotoxicity.[/FONT]
[FONT=&quot]The use of a liver detoxification supplement such as Liver Stabil, Liv-52, or Essentiale Forte is advised while taking any hepatotoxic anabolic/androgenic steroids.[/FONT]
[h=3]Side Effects (Cardiovascular):[/h][FONT=&quot]Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Methylandrostenediol has a strong effect on the hepatic management of cholesterol due to its structural resistance to liver breakdown and (with the oral) route of administration. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.[/FONT]
[FONT=&quot]To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.[/FONT]
[h=3]Side Effects (Testosterone Suppression):[/h][FONT=&quot]All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.[/FONT]
[FONT=&quot]The above side effects are not inclusive. For more detailed discussion of potential side effects, see the Steroid Side Effects page.[/FONT]
[h=3]Administration (General):[/h][FONT=&quot]Studies have shown that taking an oral anabolic steroid with food may decrease its bioavailability. This is caused by the fat-soluble nature of steroid hormones, which can allow some of the drug to dissolve with undigested dietary fat, reducing its absorption from the gastrointestinal tract. For maximum utilization, oral forms of this steroid should be taken on an empty stomach.[/FONT]
[h=3]Administration (Men):[/h][FONT=&quot]Early prescribing guidelines for Stenediol recommend a dosage of 25 mg given 2 to 5 times per week by oral, buccal, or intramuscular route. For physique- or performance-enhancing purposes, a typical dosage is in the range of 25-50 mg daily for the oral form, and 200-400 mg per week with the injectable. In order to keep blood levels more even with the injectable, it is generally administered once every three to four days. Cycles generally last for no more than 6 to 8 weeks, in an effort to minimize hepatotoxicity and strain on the liver and cholesterol values. This level of use is sufficient for moderate gains in muscle size and strength, which may be accompanied by a low level of water retention.[/FONT]
[FONT=&quot]While it may be possible to use methylandrostenediol alone for muscle-building purposes, it is most often combined with other anabolics for a stronger effect. Combined with Deca-Durabolin® or Equipoise®, for example, measurable gains of hard muscle mass, without an extreme level of water retention, may be noticed. This is the general composition of most Australian vet blends that include methylandrostenediol. When looking for a more pronounced gain in mass, a stronger androgen such as testosterone may be added. The resulting growth can be quite exceptional, but the user will also have to deal with a much stronger set of estrogenic side effects. The drug sometimes also combines well with non-aromatizing anabolics such as Winstrol®, Primobolan®, or oxandrolone. The result here should be a more pronounced effect on muscle hardness, with a moderate gain of solid lean tissue.[/FONT]
[h=3]Administration (Women):[/h][FONT=&quot]Early prescribing guidelines for Stenediol recommend a dosage of 25 mg given 2 to 5 times per week by oral, buccal, or intramuscular route. Methylandrostenediol is generally not recommended for women for physique- or performance-enhancing purposes due to its androgenic nature and tendency to produce virilizing side effects.[/FONT]
[h=3]Availability:[/h][FONT=&quot]Pharmaceutical preparations containing Methandriol remain scarce. The only place where this steroid is still produced in an volume is Australia, where a few veterinary preparations include methandriol in their blends. These products are rarely traded in international commerce due to tight controls on anabolic steroids in that country.[/FONT]

 

[repitup]

ya got a write up on inj superdrol

 

[Pcushion]

Let me browse through my books and see. If I do I will post it up for you.

 

[Pcushion]

Parabolan was just being discussed on one of the boards I am assigned so
I figured why not.

Androgenic 500
Anabolic 500
Standard Nandrolone acetate
Chemical Name 17beta-Hydroxyestra-4,9,11-trien-3-one
Estrogenic Activity none
Progestational Activity moderate
​

[h=3]Description:[/h][FONT=&quot]Parabolan is the most recognized brand name for trenbolone hexahydrobenzylcarbonate, a slow-acting injectable ester of the potent anabolic steroid trenbolone. Trenbolone appears most commonly as trenbolone acetate, which is a much faster-acting form of the drug (see: trenbolone acetate). The hexahydrobenzylcarbonate ester used here extends the release of trenbolone for more than 2 weeks, which has always been thought of as more suitable for human use due to the less frequent injection schedule. The base steroid trenbolone is roughly three times more androgenic than testosterone, making it a fairly potent androgen. It also displays about 3 times greater tissue-building activity in comparison to its androgenic properties, making its official classification as that of an anabolic steroid. The muscle-building effect of trenbolone is often compared to such popular bulking agents as testosterone or Dianabol, but without the same estrogenrelated side effects. It is most commonly identified as a lean-mass-building drug, and is extremely popular with athletes for its ability to promote the rapid buildup of strength, muscle size, and definition.[/FONT]
[h=3]History:[/h][FONT=&quot]The first long-acting trenbolone ester (undecanoate) was studied in 1967, described during a series of experiments into synthetic anabolic steroids by Roussel-UCLAF.[SUP]571[/SUP]Trenbolone hexahydrobenzylcarbonate was a subsequent and uniquely French slant to this long-acting anabolic steroid, possessing an unusual but roughly equivalent compound. Trenbolone hexahydrobenzylcarbonate was developed into a medicine by Negma Laboratoires in France, which sold the drug under the Parabolan trade name. It was also sold for a period of time as Hexabolan, a name that referred to the unusual ester it possesses. Trenbolone hexahydrobenzylcarbonate is the only known form of trenbolone ever produced as a medicine for human consumption. The most notable appearance of trenbolone comes as trenbolone acetate, which is used widely and exclusively in veterinary medicine.[/FONT]
[FONT=&quot]Parabolan was prescribed in France as a protein-sparing anabolic agent in cases of cachexia (lean body mass wasting) and malnutrition, as well as to combat certain forms of osteoporosis. Its prescribing guidelines included recommendations for the treatment of androgen-sensitive populations, such as women and the elderly. Owing to its moderate androgenic properties, however, the drug was contraindicated in children, especially young females. Parabolan remained on the French market for a very long time, although it was finally discontinued (voluntarily) by Negma in 1997. For a brief period of time it seemed that the demise of Parabolan would mark the end of human-use trenbolone preparations, as no other medicine approved for human use was known to exist worldwide at the time. A very small number of Parabolan preparations have been brought to market since, however, so while the drug is still poorly available, it is not completely defunct.[/FONT]
[h=3]How Supplied:[/h][FONT=&quot]Parabolan is no longer produced as a prescription drug product. When manufactured in France it came in the form of a 1.5 mL ampule containing 76 mg of steroid (product information lists this as equivalent to 50 mg of base trenbolone).[/FONT]
[h=3]

[/h][h=3]Structural Characteristics:[/h][FONT=&quot]Trenbolone is a modified form of nandrolone. It differs by the introduction of double bonds at carbons 9 and 11, which inhibit aromatization (9-ene), increase androgen-binding affinity,[SUP]572[/SUP] and slows its metabolism. The resulting steroid is significantly more potent as both an anabolic and an androgen than its nandrolone base. The trenbolone here is modified with a hexahydrobenzylcarbonate ester at the 17-beta hydroxyl group, so that the free steroid is released more slowly from the area of injection.[/FONT]
[h=3]Side Effects (Estrogenic):[/h][FONT=&quot]Trenbolone is not aromatized by the body, and is not measurably estrogenic. It is of note, however, that this steroid displays significant binding affinity for the progesterone receptor (slightly stronger than progesterone itself ).[SUP]573 574[/SUP] The side effects associated with progesterone are similar to those of estrogen, including negative feedback inhibition of testosterone production and enhanced rate of fat storage. Progestins also augment the stimulatory effect of estrogens on mammary tissue growth. There appears to be a strong synergy between these two hormones here, such that gynecomastia might even occur with the help of progestins, without excessive estrogen levels. The use of an anti-estrogen, which inhibits the estrogenic component of this disorder, is often sufficient to mitigate gynecomastia caused by progestational anabolic/androgenic steroids. Note that progestational side effects are more common when trenbolone is being taken with other aromatizable steroids.[/FONT]
[h=3]Side Effects (Androgenic):[/h][FONT=&quot]Although classified as an anabolic steroid, trenbolone is sufficiently androgenic. Androgenic side effects are still common with this substance, and may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Women are also warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Additionally, the 5-alpha reductase enzyme does not metabolize trenbolone[SUP]575[/SUP], so its relative androgenicity is not affected by finasteride or dutasteride.[/FONT]
[h=3]Side Effects (Hepatotoxicity):[/h][FONT=&quot]Trenbolone is not c-17 alpha alkylated, and is generally not considered a hepatotoxic steroid; liver toxicity is unlikely. This steroid does have a strong level of resistance to hepatic breakdown, however, and severe liver toxicity has been noted in bodybuilders abusing trenbolone.[SUP]576[/SUP]Although unlikely, hepatotoxicity cannot be completely excluded, especially with high doses.[/FONT]
[h=3]Side Effects (Cardiovascular):[/h][FONT=&quot]Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Due to its non-aromatizable nature and strong resistance to metabolism, trenbolone has a moderate to strong (negative) impact on lipid values and atherogenic risk. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.[/FONT]
[FONT=&quot]To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.[/FONT]
[h=3]Side Effects (Testosterone Suppression):[/h][FONT=&quot]All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention. In experimental studies, trenbolone was determined to be approximately three times stronger at suppressing gonadotropins than testosterone on a milligram for milligram basis.[/FONT]
[FONT=&quot]The above side effects are not inclusive. For more detailed discussion of potential side effects, see the Steroid Side Effects section of this book.[/FONT]
[h=3]Administration (Men):[/h][FONT=&quot]Parabolan was generally administered in a clinical dosage of 3 ampules per month. Therapy was initiated the first month with all 3 ampules given over the first 15 days. During the subsequent 3 months, one injection (76 mg) was given every 10 days. For physique- or performance-enhancing purposes, trenbolone hexahydrobenzylcarbonate is most often administered at a dosage of 152-220 mg per week. The drug would be taken in cycles ranging from 6 to 12 weeks. Although a weekly administration schedule would be more than sufficient, athletes usually injected a single ampule (76mg) at a time, and the total amount would be spread evenly throughout the week. Although not necessary, this type of schedule helps to reduce injection volume per application. The results with the use of trenbolone hexahydrobenzylcarbonate should be a visibly more muscular physique (larger, leaner), and, if body fat levels are low enough, that hard ripped look most valued by dieting and competitive bodybuilders.[/FONT]
[FONT=&quot]While this drug is quite potent when used alone, it is sometimes combined with other steroids for an even greater effect. Leading up to a show one could successfully add a non-aromatizing anabolic such as Winstrol® or Primobolan®. Such combinations will elicit a greater level of density and hardness to the build, often proving dramatic for a stage appearance. We could also look for bulk with this drug, and addition stronger compounds like Dianabol or Testosterone. While the mass gain would be quite formidable with such a stack, some level of water retention would probably also accompany it. Moderately effective anabolics such Deca-Durabolin® or Equipoise® would be somewhat of a halfway point, providing extra strength and mass but without the same level of water bloat we see with more readily aromatized steroids.[/FONT]
[h=3]Administration (Women):[/h][FONT=&quot]Parabolan was generally administered in a clinical dosage of 3 ampules per month. Therapy was initiated the first month with all 3 ampules given over the first 15 days. During the subsequent 3 months, one injection (76mg) was given every 10 days. Given the risk of virilization, lower doses were likely used by physicians with many female patients. This agent is generally not recommended for women for physique- or performance-enhancing purposes due to strong androgenic nature and tendency to produce virilizing side effects.[/FONT]
[h=3]Availability:[/h][FONT=&quot]Pharmaceutical preparations containing trenbolone hexahydrobenzylcarbonate remain scarce.[/FONT]

 

[Pcushion]

Androgenic: 1,800
Anabolic 4,100
Standard Methyltestosterone (oral)
Chemical Names 7,17-dimethyl-19-norandrost-4-en-3-one-17b-ol, 17beta-Hydroxy-7alpha,17-dimethylestr-4-en-3-one
Estrogenic Activity high
Progestational Activity high
​

[h=3]Description:[/h][FONT=&quot]Mibolerone is an oral anabolic steroid, structurally derived from nandrolone. This agent is specifically 7,17-dimethylated nandrolone, significantly more potent as an anabolic and androgenic agent than its non-methylated parent. Over the years, mibolerone has earned a reputation among bodybuilders as being one of the strongest steroids ever made. This is correct in a technical sense, as it is one of only a select few commercial steroid products effective in microgram, not milligram, amounts. During standard animal assays, mibolerone was determined to have 41 times the anabolic activity of methyltestosterone when given orally. In contrast, it had only 18 times the androgenic activity. Although both properties are strongly pronounced with this agent, it retains a primarily anabolic character (in a relative sense). Estrogenic and progestational properties are also very pronounced with this drug, however. Among athletes it is most commonly applied during bulking phases of training, or to stimulate aggression before a workout or competition.[/FONT]
[h=3]History:[/h][FONT=&quot]Mibolerone was first described in 1963.[SUP]430[/SUP] It was developed into a veterinary medicine during the 1960’s by Upjohn, which sold the drug under the brand name Cheque Drops. The preparation contained 100 mcg/ml of steroid in a 55 mL bottle, for a total steroid content of 5.5 milligrams (illustrating the high relative potency of mibolerone). Pharmacia & Upjohn later also sold a preparation called Cheque Medicated Dog Food, of obvious composition. The drug was administered orally, and had been used to interrupt the estrous cycle of female dogs, preventing them from going into heat. It is approved for use in an animal for no longer than 24 months. Use of the drug is considered carefully by most veterinarians, mainly because longer-term administration can produce side effects such as clitoral enlargement, aggression, urinary difficulties, and liver damage.[/FONT]
[FONT=&quot]Among athletes, mibolerone has always been seen with a high level of mystique, perhaps partly due to its limited availability. Those actually familiar with the Upjohn (then Pharmacia & Upjohn) product were likely disappointed during the early 2000’s, when the Cheque products were officially discontinued by the manufacturer. The company, now Pfizer Animal Health, presently lists no mibolerone-containing products on its inventory, despite retaining the rights to market the drug. Mibolerone is still available in the U.S., but only in generic form from a private compounding pharmacy, obtained under special order by a licensed veterinarian. The removal of the Pharmacia & Upjohn products from the U.S. market marked the commercial end of mibolerone. No prescription preparation, human or veterinary, is currently known to contain mibolerone worldwide.[/FONT]
[h=3]How Supplied:[/h][FONT=&quot]Mibolerone is no longer available as a prescription drug product. When produced it most commonly came in the form of an oral solution based in propylene glycol, carrying 100mcg of steroid per milliliter in a 55 mL bottle.[/FONT]
[FONT=&quot]

[/FONT]
[h=3]Structural Characteristics:[/h][FONT=&quot]Mibolerone is a modified form of nandrolone. It differs by 1) the addition of a methyl group at carbon 17-alpha to protect the hormone during oral administration and 2) the introduction of a methyl group at carbon 7 (alpha), which inhibits 5-alpha reduction and increases relative androgenicity. 7,17-dimethylated steroids also tend to be very resistant to metabolism and serum-binding proteins, greatly enhancing their relative biological activity.[/FONT]
[h=3]Side Effects (Estrogenic):[/h][FONT=&quot]Mibolerone is aromatized by the body, and is considered a highly estrogenic steroid due to its conversion to 7,17-dimethylestradiol (an estrogen with high biological activity). Gynecomastia may be a concern during treatment, especially when higher than normal therapeutic doses are used. At the same time water retention can become a problem, causing a notable loss of muscle definition as both subcutaneous water retention and fat levels build. To avoid strong estrogenic side effects, it may be necessary to use an anti-estrogen such as Nolvadex®. One may alternately use an aromatase inhibitor like Arimidex® (anastrozole), which is a more effective remedy for estrogen control. Aromatase inhibitors, however, can be quite expensive in comparison to standard estrogen maintenance therapies, and may also have negative effects on blood lipids.[/FONT]
[FONT=&quot]It is of note that mibolerone also displays strong activity as a progestin in the body. The side effects associated with progesterone are similar to those of estrogen, including negative feedback inhibition of testosterone production and enhanced rate of fat storage. Progestins also augment the stimulatory effect of estrogens on mammary tissue growth. There appears to be a strong synergy between these two hormones here, such that gynecomastia might even occur with the help of progestins without excessive estrogen levels being present. The use of an anti-estrogen, which inhibits the estrogenic component of this disorder, is often sufficient to mitigate gynecomastia caused by mibolerone.[/FONT]
[h=3]Side Effects (Androgenic):[/h][FONT=&quot]Although classified as an anabolic steroid, androgenic side effects are still common with this substance. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Individuals sensitive to the androgenic effects of this steroid may find a milder anabolic such as Deca-Durabolin® to be more comfortable. Women are additionally warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Note that 7-methylation inhibits steroid 5-alpha reduction.[SUP]431[/SUP] The relative androgenicity of mibolerone is not affected by the concurrent use of finasteride or dutasteride.[/FONT]
[h=3]Side Effects (Hepatotoxicity):[/h][FONT=&quot]Mibolerone is a c17-alpha alkylated compound. This alteration protects the drug from deactivation by the liver, allowing a very high percentage of the drug entry into the bloodstream following oral administration. C17-alpha alkylated anabolic/androgenic steroids can be hepatotoxic. Prolonged or high exposure may result in liver damage. In rare instances life-threatening dysfunction may develop. It is advisable to visit a physician periodically during each cycle to monitor liver function and overall health. Intake of c17-alpha alkylated steroids is commonly limited to 6-8 weeks, in an effort to avoid escalating liver strain. Severe liver complications are rare given the periodic nature in which most people use oral anabolic/androgenic steroids, although cannot be excluded with this steroid, especially with high doses and/or prolonged administration periods. Note that U.S. prescribing information for Cheque Drops mentions only one human study being conducted on mibolerone, and that the study was terminated early due to high hepatotoxicity.[/FONT]
[FONT=&quot]The use of a liver detoxification supplement such as Liver Stabil, Liv-52, or Essentiale Forte is advised while taking any hepatotoxic anabolic/androgenic steroids.[/FONT]
[h=3]Side Effects (Cardiovascular):[/h][FONT=&quot]Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Mibolerone has a strong effect on the hepatic management of cholesterol due to its structural resistance to liver breakdown and route of administration. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.[/FONT]
[FONT=&quot]To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.[/FONT]
[h=3]Side Effects (Testosterone Suppression):[/h][FONT=&quot]All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.[/FONT]
[FONT=&quot]The above side effects are not inclusive. For more detailed discussion of potential side effects, see the Steroid Side Effects section of this book.[/FONT]
[h=3]Administration (General):[/h][FONT=&quot]Studies have shown that taking an oral anabolic steroid with food may decrease its bioavailability.[SUP]432[/SUP] This is caused by the fat-soluble nature of steroid hormones, which can allow some of the drug to dissolve with undigested dietary fat, reducing its absorption from the gastrointestinal tract. For maximum utilization, this steroid should be taken on an empty stomach.[/FONT]
[h=3]Administration (Men):[/h][FONT=&quot]Mibolerone was never approved for use in humans. Prescribing guidelines are unavailable. In the athletic arena, the drug is used intermittently due to its high level of hepatotoxicity, with cycles usually lasting no more than 6 weeks followed by 6-8 weeks off. A daily dosage of 200 to 500mcg is most common for bodybuilding purposes. This level is typically sufficient for gains in strength and muscle mass (bulk). The high progestational and estrogenic activity of mibolerone makes it of little value in speed and endurance sports, causing an unwanted retention of water weight.[/FONT]
[h=3]Administration (Women):[/h][FONT=&quot]Mibolerone was never approved for use in humans. Prescribing guidelines are unavailable. Mibolerone is generally not recommended for women for physique- or performance-enhancing purposes due to its very strong nature and tendency to produce virilizing side effects.[/FONT]
[h=3]Availability:[/h][FONT=&quot]Mibolerone is sold in the U.S. as a compounded veterinary medicine only. No commercial preparations containing this drug are known to exist worldwide. Mibolerone remains available on the black market in underground preparations only.[/FONT]

 

[Pcushion]

Androgenic: 30
Anabolic: 320
Standard: Methyltestosterone (oral)
Chemical Name: 17beta-hydroxy-17-methyl-5alpha-androstano
[3,2-c]pyrazole
Estrogenic Activity: none
Progestational Activity: not significant



Description:

Winstrol is the most widely recognized trade name for the drug stanozolol. Stanozolol is a derivative of dihydrotestosterone, chemically altered so that the hormone’s anabolic (tissue-building) properties are greatly amplified and its androgenic activity minimized. Stanozolol is classified as an “anabolic” steroid, and exhibits one of the strongest dissociations of anabolic to androgenic effect among commercially available agents. It also cannot be aromatized into estrogens. Stanozolol is the second most widely used oral steroid, succeeded in popularity only by Dianabol (methandrostenolone). It is favored for its ability to promote muscle growth without water-retention, making it highly valued by dieting bodybuilders and competitive athletes.
History:

Stanozolol was first described in 1959.[SUP]613[/SUP] It was developed into a medicine by Winthrop Laboratories in Great Britain. Parent firm (Sterling) filed for U.S. patent on the agent in 1961.[SUP]614[/SUP] Stanozolol was officially released to the U.S. prescription drug market in 1962 under the brand name Winstrol. Stanozolol was initially prescribed for a variety of medical purposes, including the induction of appetite and lean tissue gain in cases of weight loss associated with many malignant and non-malignant diseases, the preservation of bone mass during osteoporosis, the promotion of liner growth in children with growth failure, as an anti-catabolic during prolonged corticosteroid therapy or for post-operative and post-trauma (burns, fractures) patients, and even to treat debility in the elderly.
The FDA’s control over the prescription drug market had tightened by the mid-1970’s, and the indicated uses for Winstrol were soon narrowed. During this time the FDA officially supported that Winstrol was “Probably Effective” as an adjunct therapy for treating osteoporosis, and for promoting growth in pituitary-deficient dwarfism. With this position, Winthrop was given more time to sell and study the agent. Winthrop was able to continually satisfy the FDA regarding Winstrol’s validity as a therapeutic agent, and it remained in the U.S. throughout the 1980’s and 1990’s, a time when many other anabolic steroids were disappearing from the marketplace. Stanozolol was also showing some promise during this period for improving red blood cell concentrations, combating breast cancer, and (more recently) treating angioedema, a disorder characterized by the swelling of subdermal tissues, often with hereditary causes.
Winthrop went through a number of corporate changes during the 1990’s, including a 1991 merger with Elf Sanofi to form Sanofi Winthrop. Sanofi Winthrop continued on to sell Winstrol in the U.S. for approximately 10 more years, before finally discontinuing the medication because of “manufacturing issues” (Searle was actually making the product for Sanofi at the time, and had reportedly ceased production). In 2003, the rights to Winstrol were officially transferred to Ovation ***************. Winstrol remains an approved drug on the U.S. ************** market, although is not under active production by Ovation label. All forms of Winstrol are presently unavailable in the U.S., although the Winstrol brand remains available in Spain. Numerous other brands and generic forms of the drug are produced in other countries, in both human and veterinary drug markets.
How Supplied:

Stanozolol is widely available in both human and veterinary drug markets. Composition and dosage may vary by country and manufacturer. Stanozolol was originally designed as an oral anabolic steroid, containing 2mg of drug per tablet (Winstrol). Other brands commonly contain 5 mg or 10 mg per tablet. Stanozolol can also be found in injectable preparations. These are most commonly water-based suspensions carrying 50 mg/ml of steroid.

Structural Characteristics:

Stanozolol is a modified form of dihydrotestosterone. It differs by: 1) the addition of a methyl group at carbon 17-alpha to protect the hormone during oral administration and 2) the attachment of a pyrazol group to the A-ring, replacing the normal 3-keto group (this gives stanozolol the chemical classification of a heterocyclic steroid). When viewed in the light of 17-alpha methyldihydrotestosterone, the A-ring modification on stanozolol seems to considerably increase its anabolic strength while reducing its relative androgenicity.
Stanozolol has a much weaker relative binding affinity for the androgen receptor than testosterone or dihydrotestosterone. At the same time it displays a much longer half-life and lower affinity for serum binding proteins in comparison. These features (among others) allow stanozolol to be a very potent anabolic steroid in spite of a weaker affinity for receptor binding. Recent studies have additionally confirmed that its primary mode if action involves interaction with the cellular androgen receptor.[SUP]615[/SUP] Although not fully elucidated, stanozolol may have additional (some potentially unique) properties with regard to antagonism of the progesterone receptor, Low Affinity Glucocorticoid-binding Site interaction, and AR/PR/GR independent activities.[SUP]616 617 618[/SUP]In therapeutic doses stanozolol does not have significant progestational activity.[SUP]619[/SUP]
Stanozolol is known to strongly suppress levels of SHBG (sex hormone-binding globulin). This trait is characteristic of all anabolic/androgenic steroids, although its potency and form of administration make oral Winstrol® particularly effective in this regard. One study with a group of 25 normal males demonstrated a 48.4% reduction in SHBG after only 3 days of use.[SUP]620[/SUP]The dose administered was .2mg/kg, or roughly 18mg for a person weighing 200lbs. Plasma binding proteins such as SHBG act to temporarily constrain steroid hormones from exerting activity in the body, and effectively reduce the available percentage of free (active) steroid. Oral stanozolol may be useful for providing a greater percentage of unbound steroid in the body, especially when taken in combination with a hormone that is more avidly bound by SHBG, such as testosterone.
Side Effects (Estrogenic):

Stanozolol is not aromatized by the body, and is not measurably estrogenic. An anti-estrogen is not necessary when using this steroid, as gynecomastia should not be a concern even among sensitive individuals. Since estrogen is the usual culprit with water retention, stanozolol instead produces a lean, quality look to the physique with no fear of excess subcutaneous fluid retention. This makes it a favorable steroid to use during cutting cycles, when water and fat retention are major concerns. Stanozolol is also very popular among athletes in combination strength/speed sports such as Track and Field. In such disciplines one usually does not want to carry around excess water weight, and may find the raw muscle-growth brought about by stanozolol to be quite favorable over the lower quality mass gains of aromatizable agents.
Side Effects (Androgenic):

Although classified as an anabolic steroid, androgenic side effects are still common with this substance. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Women are also warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Additionally, the 5-alpha reductase enzyme does not metabolize stanozolol, so its relative androgenicity is not affected by finasteride or dutasteride. Stanozolol is a steroid with relatively low androgenic activity in relation to its tissue-building actions, making the threshold for strong androgenic side effects comparably higher than more androgenic agents such as testosterone, methandrostenolone, or fluoxymesterone.
Side Effects (Hepatotoxicity):

Stanozolol is a c17-alpha alkylated compound. This alteration protects the drug from deactivation by the liver, allowing a very high percentage of the drug entry into the bloodstream following oral administration. C17-alpha alkylated anabolic/androgenic steroids can be hepatotoxic. Prolonged or high exposure may result in liver damage. In rare instances life-threatening dysfunction may develop. It is advisable to visit a physician periodically during each cycle to monitor liver function and overall health. Intake of c17-alpha alkylated steroids is commonly limited to 6-8 weeks, in an effort to avoid escalating liver strain.
Stanozolol appears to offer less hepatic stress than an equivalent dose of Dianabol (methandrostenolone). Studies giving 12mg of stanozolol per day for 27 weeks failed to demonstrate clinically-significant changes in markers of liver function, including serum aspartate amino-transferase, alanine amino-transferase, gamma-glutamyltransferase, bilirubin, and alkaline phosphatase.[SUP]621[/SUP] Relative hepatotoxicity increases as the dosage escalates, so hepatic dysfunction should still be a concern. In rare instances, high doses (alone or in combination with other steroids) have been implicated in cases of serious life-threatening hepatotoxicity in bodybuilders. Injectable stanozolol has also been implicated in severe hepatotoxicity in an otherwise healthy bodybuilder,[SUP]622[/SUP] and should not be used as an alternative medication when liver toxicity precludes oral stanozolol use.
The use of a liver detoxification supplement such as Liver Stabil, Liv-52, or Essentiale Forte is advised while taking any hepatotoxic anabolic/androgenic steroids.
Side Effects (Cardiovascular):

Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Stanozolol has a strong effect on the hepatic management of cholesterol due to its structural resistance to liver breakdown, non-aromatizable nature, and route of administration. Studies using an oral dose of 6 mg per day for six weeks demonstrated a mean serum HDL reduction of 33% in healthy male weight-training subjects, which was combined with a 29% increase in serum LDL.[SUP]623[/SUP]Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction. Injectable stanozolol has also been documented to produce strong negative changes in serum lipids. One study was carried out on a group of 12 healthy male subjects, and demonstrated a measurable reduction in HDL cholesterol values, as well as an increase in LDL and total cholesterol values, following a single injection of 50 mg.[SUP]624[/SUP] These changes persisted for 4 weeks after the drug was administered, and represent a potential increased risk for developing arteriosclerosis. Injectable stanozolol should not be used as an alternative medication when cardiovascular risk factors preclude oral stanozolol use.
To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.
Side Effects (Testosterone Suppression):

All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Stanozolol is no exception, and is noted for its strong influence on the hypothalamic-pituitary-testicular axis. Clinical studies giving 10 mg per day to healthy male subjects for 14 days caused the mean plasma testosterone level to fall by 55%.[SUP]625[/SUP] Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.
The above side effects are not inclusive. For more detailed discussion of potential side effects, see the Steroid Side Effects section.
Administration (General):

Studies have shown that taking an oral anabolic steroid with food may decrease its bioavailability.[SUP]626[/SUP] This is caused by the fat-soluble nature of steroid hormones, which can allow some of the drug to dissolve with undigested dietary fat, reducing its absorption from the gastrointestinal tract. For maximum utilization, oral forms of stanozolol should be taken on an empty stomach.
There can be large discrepancies in the steroid particle size between injectable stanozolol preparations. For example, Winstrol from Zambon (Spain) was designed for human use, and uses a refined powder that will pass through a 27-gauge needle. Winstrol®-V is a veterinary product in the U.S. and Canada, and has larger particles that will jam in needles smaller than 22-gauge. Solutions that utilize a larger particle size may also cause more discomfort at the site of injection. Injectable forms of stanozolol can be taken in measured oral doses should injection prove intolerable.
Administration (Men):

The original prescribing guidelines for Winstrol called for a daily dosage of 6 mg, which was administered on a schedule of one 2 mg tablet three times per day. The usual dosage for physique- or performance-enhancing purposes is between 15 mg and 25 mg per day, or three to five 5 mg tablets, taken for no longer than 6-8 weeks. Injectable Winstrol is generally recommended at a clinical dosage of one 50 mg injection every 2-3 weeks. When used for physique- or performance-enhancing purposes, a dosage of 50 mg every other day is most commonly applied. Veterinary stanozolol preparations with a larger particle size will be more slowly dispersed by the body, and are commonly given at 75 mg every third day. Doses of 50 mg per day with injectable stanozolol are not uncommon, although probably not advised. Note that injectable forms of the drug are expected to have, milligram for milligram, a greater anabolic effect than oral.[SUP]627[/SUP]
Stanozolol is often combined with other steroids for a more dramatic result. For example, while bulking one might opt to add in 200-400 mg of a testosterone ester (cypionate, enanthate, or propionate) per week. The result should be a considerable gain in new muscle mass, with a more comfortable level of water and fat retention than if taking a higher dose of testosterone alone. For dieting phases, one might alternately combine stanozolol with a non-aromatizing steroid such as 150 mg per week of a trenbolone ester or 200-300 mg of Primobolan® (methenolone enanthate). Such stacks are highly favored for increasing definition and muscularity. An in-between (lean mass gain) might be to add in 200-400 mg of a low estrogenic compound like Deca-Durabolin® (nandrolone decanoate) or Equipoise® (boldenone undecylenate).
Administration (Women):

The original prescribing guidelines for Winstrol called for a daily dosage of 4 mg (one 2mg tablet twice daily) with young women particularly susceptible to the androgenic effects of anabolic steroids. This dosage was increased to 6mg (the same as the recommended dose for males) when necessary. When used for physique- or performance-enhancing purposes, a dosage of 5 mg to 10 mg daily is most common, taken for no longer than 4-6 weeks. Injectable Winstrol is generally recommended at a clinical dose of 50 mg every 2-3 weeks. The injectable is usually not advised with women for physique- or performance-enhancing purposes, as it allows for less control over blood hormone levels. Those women who absolutely must use the injectable commonly administer 25 mg every 3 or 4 days. Although this compound is weakly androgenic, the risk of virilization symptoms cannot be completely excluded, even at therapeutic doses.
Availability:

Stanozolol remains widely available as a ************** product. Its production has been shifting to less regulated markets (mainly in Asia) in recent years, however, which likely reflects declining interest in using stanozolol as a medicinal product in the West, and the continuing high demand for this drug among athletes and bodybuilders

 

[Oldman85]

I love me some Winstrol. I don’t seem to get creaky joints, just a good dry look.

 

[Pcushion]

It never gave me joint issues either but I also didn’t run it past 4 weeks.

 

[Pcushion]

[FONT=&quot]Omnadren 250 (in its original formulation), was an oil-based injectable testosterone blend that contained four different testosterone esters: testosterone propionate (30 mg); testosterone phenylpropionate (60 mg); testosterone isocaproate (60 mg); and testosterone caproate (100 mg). Being a four-component testosterone blend, this preparation was most commonly compared to Sustanon® 250. While it did contain testosterone propionate, phenylpropionate, and isocaproate in the same strengths as Sustanon®, the last ester is different. It was a slightly shorter-acting drug, making Omnadren® more analogous to Testoviron® (the caproate ester is one carbon shorter than enanthate) than Sustanon® 250. Please note that there were even older versions of Omnadren® listing isohexanoate and hexanoate as the final two ingredients, which are simply different words for isocaproate and caproate.[/FONT]
[h=3]History:[/h][FONT=&quot]Omnadren® 250 was developed in Poland by Polfa during the years of Soviet control. Its formulation (original) is very similar to that of Sustanon® 250, barring the substitution of one of the component esters. This was likely done to avoid patent issues with the international pharmaceutical giant Organon, which exclusively controlled the global supply of Sustanon® 250. In clinical medicine, Omnadren® 250 was used most commonly to treat adult men suffering from low androgen levels, usually noticing symptoms of impotence or hormonal disturbance of spermatogenesis. This drug was also used on occasion to treat adolescents with delayed puberty, and women with advanced breast or endometrial cancer.[/FONT]
[FONT=&quot]The manufacture of Omnadren® 250 under the Polfa label was discontinued in 1994. That year, the newly privatized Polfa firm was renamed Jelfa, mainly to distinguish itself from other firms that use a Polfa prefix as part of their names. Jelfa continued to produce Omnadren® 250 for the domestic market, which remained available without interruption in the same familiar 5-pack of ampules (albeit with a new company label and logo) for years after. Today, Jelfa continues to market Omnadren® 250 in Poland, as well as in many neighboring markets including Russia, Ukraine, Kazakhstan, Uzbekistan, Kurdistan, Kyrgyzstan, Armenia, Moldavia, Latvia, Lithuania, Azerbaijan, Georgia, and Belarus, however the formulation has recently changed. All Omnadren 250 sold today carries the same exact formulation as Sustanon 250. This profile refers to the original formulation only, which is now unavailable worldwide.[/FONT]
[h=3]How Supplied:[/h][FONT=&quot]Omnadren® 250 (original formulation) in no longer available. When manufactured, it was supplied in 1 mL glass ampules containing an oily solution; sold in boxes of 5 ampules.[/FONT]
[h=3]

[/h][h=3]Structural Characteristics:[/h][FONT=&quot]Omnadren® 250 contains a mixture of four testosterone compounds, which where modified with the addition of carboxylic acid esters (propionic, propionic phenyl ester, isocaproic, and caproic acids) at the 17-beta hydroxyl group. Esterified forms of testosterone are less polar than free testosterone, and are absorbed more slowly from the area of injection. Once in the bloodstream, the ester is removed to yield free (active) testosterone. Esterified forms of testosterone are designed to prolong the window of therapeutic effect following administration, allowing for a less frequent injection schedule compared to injections of free (unesterified) steroid. Omnadren® 250 is designed to provide a rapid peak in testosterone levels (24-48 hours after injection), and maintain physiological concentrations for approximately 14 days.[/FONT]
[h=3]Side Effects (Estrogenic):[/h][FONT=&quot]Testosterone is readily aromatized in the body to estradiol (estrogen). The aromatase (estrogen synthetase) enzyme is responsible for this metabolism of testosterone. Elevated estrogen levels can cause side effects such as increased water retention, body fat gain, and gynecomastia. Testosterone is considered a moderately estrogenic steroid. An anti-estrogen such as clomiphene citrate or tamoxifen citrate may be necessary to prevent estrogenic side effects. One may alternately use an aromatase inhibitor like Arimidex® (anastrozole), which more efficiently controls estrogen by preventing its synthesis. Aromatase inhibitors can be quite expensive in comparison to anti-estrogens, however, and may also have negative effects on blood lipids.[/FONT]
[FONT=&quot]Estrogenic side effects will occur in a dose-dependant manner, with higher doses (above normal therapeutic levels) of testosterone more likely to require the concurrent use of an anti-estrogen or aromatase inhibitor. Since water retention and loss of muscle definition are common with higher doses of testosterone, this drug is usually considered a poor choice for dieting or cutting phases of training. Its moderate estrogenicity makes it more ideal for bulking phases, where the added water retention will support raw strength and muscle size, and help foster a stronger anabolic environment.[/FONT]
[h=3]Side Effects (Androgenic):[/h][FONT=&quot]Testosterone is the primary male androgen, responsible for maintaining secondary male sexual characteristics. Elevated levels of testosterone are likely to produce androgenic side effects including oily skin, acne, and body/facial hair growth. Men with a genetic predisposition for hair loss (androgenetic alopecia) may notice accelerated male pattern balding. Those concerned about hair loss may find a more comfortable option in nandrolone decanoate, which is a comparably less androgenic steroid. Women are warned of the potential virilizing effects of anabolic/androgenic steroids, especially with a strong androgen such as testosterone. These may include deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement.[/FONT]
[FONT=&quot]In androgen-responsive target tissues such as the skin, scalp, and prostate, the high relative androgenicity of testosterone is dependant on its reduction to dihydrotestosterone (DHT). The 5-alpha reductase enzyme is responsible for this metabolism of testosterone. The concurrent use of a 5-alpha reductase inhibitor such as finasteride or dutasteride will interfere with site-specific potentiation of testosterone action, lowering the tendency of testosterone drugs to produce androgenic side effects. It is important to remember that anabolic and androgenic effects are both mediated via the cytosolic androgen receptor. Complete separation of testosterone’s anabolic and androgenic properties is not possible, even with total 5-alpha reductase inhibition.[/FONT]
[h=3]Side Effects (Hepatotoxicity):[/h][FONT=&quot]Testosterone does not have hepatotoxic effects; liver toxicity is unlikely. One study examined the potential for hepatotoxicity with high doses of testosterone by administering 400 mg of the hormone per day (2,800 mg per week) to a group of male subjects. The steroid was taken orally so that higher peak concentrations would be reached in hepatic tissues compared to intramuscular injections. The hormone was given daily for 20 days, and produced no significant changes in liver enzyme values including serum albumin, bilirubin, alanine-amino-transferase, and alkaline phosphatases.[SUP]556[/SUP][/FONT]
[h=3]Side Effects (Cardiovascular):[/h][FONT=&quot]Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.[/FONT]
[FONT=&quot]Testosterone tends to have a much less dramatic impact on cardiovascular risk factors than synthetic steroids. This is due in part to its openness to metabolism by the liver, which allows it to have less effect on the hepatic management of cholesterol. The aromatization of testosterone to estradiol also helps to mitigate the negative effects of androgens on serum lipids. In one study, 280 mg per week of testosterone ester (enanthate) had a slight but not statistically significant effect on HDL cholesterol after 12 weeks, but when taken with an aromatase inhibitor a strong (25%) decrease was seen.[SUP]557[/SUP] Studies using 300 mg of testosterone ester (enanthate) per week for 20 weeks without an aromatase inhibitor demonstrated only a 13% decrease in HDL cholesterol, while at 600 mg the reduction reached 21%.[SUP]558[/SUP] The negative impact of aromatase inhibition should be taken into consideration before such drug is added to testosterone therapy.[/FONT]
[FONT=&quot]Due to the positive influence of estrogen on serum lipids, tamoxifen citrate or clomiphene citrate are preferred to aromatase inhibitors for those concerned with cardiovascular health, as they offer a partial estrogenic effect in the liver. This allows them to potentially improve lipid profiles and offset some of the negative effects of androgens. With doses of 600 mg or less of testosterone per week, the impact on lipid profile tends to be noticeable but not dramatic, making an anti-estrogen (for cardioprotective purposes) perhaps unnecessary. Doses of 600 mg or less per week have also failed to produce statistically significant changes in LDL/VLDL cholesterol, triglycerides, apolipoprotein B/C-III, C-reactive protein, and insulin sensitivity, all indicating a relatively weak impact on cardiovascular risk factors.[SUP]559[/SUP] When used in moderate doses, injectable testosterone esters are usually considered to be the safest of all anabolic/androgenic steroids.[/FONT]
[FONT=&quot]To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.[/FONT]
[h=3]Side Effects (Testosterone Suppression):[/h][FONT=&quot]All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Testosterone is the primary male androgen, and offers strong negative feedback on endogenous testosterone production. Testosterone-based drugs will, likewise, have a strong effect on the hypothalamic regulation of natural steroid hormones. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.[/FONT]
[FONT=&quot]The above side effects are not inclusive. For more detailed discussion of potential side effects, see the Steroid Side Effects section of this book.[/FONT]
[h=3]Administration (General):[/h][FONT=&quot]Testosterone propionate is often regarded as a painful injection. This is due to the very short carbon chain of the propionic acid ester, which can be irritating to tissues at the site of injection. Many sensitive individuals choose to stay away from this steroid completely, their bodies reacting with a pronounced soreness and low-grade fever that may last for a few days after each injection.[/FONT]
[h=3]Administration (Men):[/h][FONT=&quot]Depending on the application, the prescribing guidelines for Omnadren® 250 call for a dosage of 250 mg (1 ampule) to be injected every 3 to 4 weeks. Although active in the body for a longer time, Omnadren® 250 is usually administered on a weekly basis for muscle-building purposes. This schedule will allow for the higher doses most commonly applied by athletes, and more stable elevations in hormone level. The usual dosage among male athletes is in the range of 250-750 mg per injection, taken in cycles 6 to 12 weeks in length. This level is sufficient for most users to notice exceptional gains in muscle size and strength. Some bodybuilders have been known to use excessively high dosages of this drug (1,000 mg per week or more), although this practice is generally not advised due to the higher incidence of side effects. Testosterone is ultimately very versatile, and can be combined with many other anabolic/androgenic steroids to tailor the desired effect.[/FONT]
[h=3]Administration (Women):[/h][FONT=&quot]Omnadren® 250 is rarely used with women in clinical medicine. When applied, it is most often used to treat inoperable breast or endometrial cancer. Omnadren® 250 is not recommended for women for physique- or performance-enhancing purposes due to its strong androgenic nature, tendency to produce virilizing side effects, and slow-acting characteristics (making blood levels difficult to control).[/FONT]
[h=3]Availability:[/h][FONT=&quot]The original Omnadren 250 formulation is no longer available. Jelfa continues to use the trade name to market a steroid product, but it is now equivalent in makeup to Sustanon 250. See the Sustanon 250 profile for more information.[/FONT]

 

[Oldman85]

I don’t know what it is about the test blends, but I get less estrogenic sides than when using Test E or C. I’m also partial, as I used Sust on my first ever cycle and, boy I caught the tiger by the tail.

 

[Pcushion]

That’s how these things go. Everyone is different. My labs look better on tren than they do on eq.... who would have figured.

 

[Pcushion]

Androgenic: 22-55
Anabolic 100-200
Standard Methyltestosterone (oral)
Chemical Names 17alpha-Ethyl-17beta-hydroxyestr-4-en-3-one, 17a-ethyl-19-nortestosterone
Estrogenic Activity high
Progestational Activity high
​

[h=3]Description:[/h][FONT=&quot]Nilevar is a trade name for norethandrolone, an anabolic steroid closely related to nortestosterone (nandrolone) in structure. The activity of this steroid is that of a mild to moderate oral anabolic steroid, which is accompanied by distinguishable androgenic and estrogenic components. Although this steroid is essentially nandrolone modified (alkylated) to make oral dosing viable, it cannot be looked at simply as an oral alternative to Deca-Durabolin®. Most notably, the greatly increased estrogenicity caused by 17-alkylation makes norethandrolone much more problematic when trying to build quality (lean) muscle mass. In administering an effective amount of steroid in terms of muscle growth, the user has to deal with much more in terms of estrogenic side effects. The muscle accumulation with norethandrolone is also going to be accompanied by a high level of water and (likely) fat retention, not the quality muscularity normally associated with nandrolone decanoate.[/FONT]
[h=3]History:[/h][FONT=&quot]Norethandrolone was first described in 1954.[SUP]553[/SUP]It was developed into a medicine by Searle, which introduced it into the U.S. prescription drug market under the Nilevar brand name during the late 1950’s. The drug was originally sold as an oral tablet, an oral solution (with dropper bottle), and an injectable solution (in 25 mg ampules). The latter form of norethandrolone has been out of commerce for so long that few remember it was once also given by injection. Nilevar was prescribed for a variety of illnesses that were benefited by a protein sparing anabolic agent, Listed indications included preparation for and recovery from surgery, severe or prolonged illness, anorexia nervosa, severe burns and trauma, decubitus ulcers, osteoporosis, bone fracture healing, gastrointestinal disease, prolonged corticosteroid administration, and various forms of malnourishment in adults and children.[/FONT]
[FONT=&quot]Nilevar ultimately saw only limited success as a prescription anabolic agent. It did make its way to Europe and certain other markets, but not widely. The drug was an early functional anabolic, displaying more tissue-building properties than androgenic effects. But it also remained an agent with a troubling estrogenic side. This eventually led to norethandrolone being passed over clinically for more refined compounds as they became available. Searle decided to discontinue the sale of Nilevar in the U.S. during the 1960’s, and instead began focusing energies on its newer, more strongly anabolic, and non-estrogenic steroid oxandrolone (sold as Anavar). Most other markets carrying norethandrolone, either by Searle or other companies, soon began losing this compound as well. Today, this drug is available on a limited basis, most notably in Australia where it remains viable on the veterinary drug market.[/FONT]
[h=3]How Supplied:[/h][FONT=&quot]Nilevar is available in select veterinary drug markets. Composition and dosage may vary by country and manufacturer, but typically contain 5 or 10 mg of steroid per tablet.[/FONT]
[h=3]

[/h][h=3]Structural Characteristics:[/h][FONT=&quot]Norethandrolone is a modified form of nandrolone. It differs by the addition of an ethyl group at carbon 17-alpha to protect the hormone during oral administration.[/FONT]
[h=3]Side Effects (Estrogenic):[/h][FONT=&quot]Norethandrolone is aromatized by the body, and converts to a synthetic estrogen with a high level of biological activity (17alpha-ethyl-estradiol). As a result, it is a highly estrogenic steroid. Gynecomastia is often a concern during treatment, and may present itself quite early into a cycle (particularly when higher doses are used). At the same time water retention can become a problem, causing a notable loss of muscle definition as both subcutaneous water retention and fat levels build. Sensitive individuals may want to keep the estrogen under control with the addition of an anti-estrogen such as Nolvadex®. One may alternately use an aromatase inhibitor like Arimidex® (anastrozole), which is a more effective remedy for estrogen control. Aromatase inhibitors, however, can be quite expensive in comparison to standard estrogen maintenance therapies, and may also have negative effects on blood lipids.[/FONT]
[FONT=&quot]It is of note that norethandrolone has some additional activity as a progestin in the body.[SUP]554[/SUP]The side effects associated with progesterone are similar to those of estrogen, including negative feedback inhibition of testosterone production and enhanced rate of fat storage. Progestins also augment the stimulatory effect of estrogens on mammary tissue growth. There appears to be a strong synergy between these two hormones here, such that gynecomastia might even occur with the help of progestins without excessive estrogen levels being present. The use of an anti-estrogen, which inhibits the estrogenic component of this disorder, is often sufficient to mitigate gynecomastia caused by norethandrolone.[/FONT]
[h=3]Side Effects (Androgenic):[/h][FONT=&quot]Although classified as an anabolic steroid, androgenic side effects are still common with this substance. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Individuals sensitive to the androgenic effects of this steroid may find a milder anabolic such as Deca-Durabolin® to be more comfortable. Women are additionally warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement.[/FONT]
[FONT=&quot]Note that in androgen-responsive target tissues such as the skin, scalp, and prostate, the relative androgenicity of norethandrolone is reduced by its reduction to dihydronorethandrolone. The 5-alpha reductase enzyme is responsible for this metabolism. The concurrent use of a 5-alpha reductase inhibitor such as finasteride or dutasteride will interfere with site-specific reduction of norethandrolone action, considerably increasing the tendency of the drug to produce androgenic side effects. Reductase inhibitors should be avoided with this steroid if maintaining low relative androgenicity is desired.[/FONT]
[h=3]Side Effects (Hepatotoxicity):[/h][FONT=&quot]Norethandrolone is a c17-alpha alkylated compound. This alteration protects the drug from deactivation by the liver, allowing a very high percentage of the drug entry into the bloodstream following oral administration. C17-alpha alkylated anabolic/androgenic steroids can be hepatotoxic. Prolonged or high exposure may result in liver damage. In rare instances life-threatening dysfunction may develop. It is advisable to visit a physician periodically during each cycle to monitor liver function and overall health. Intake of c17-alpha alkylated steroids is commonly limited to 6-8 weeks, in an effort to avoid escalating liver strain. Severe liver complications are rare given the periodic nature in which most people use oral anabolic/androgenic steroids, although cannot be excluded with this steroid, especially with high doses and/or prolonged administration periods.[/FONT]
[FONT=&quot]The use of a liver detoxification supplement such as Liver Stabil, Liv-52, or Essentiale Forte is advised while taking any hepatotoxic anabolic/androgenic steroids.[/FONT]
[h=3]Side Effects (Cardiovascular):[/h][FONT=&quot]Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Norethandrolone has a strong effect on the hepatic management of cholesterol due to its structural resistance to liver breakdown and route of administration. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.[/FONT]
[FONT=&quot]To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.[/FONT]
[h=3]Side Effects (Testosterone Suppression):[/h][FONT=&quot]All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.[/FONT]
[FONT=&quot]The above side effects are not inclusive. For more detailed discussion of potential side effects, see the Steroid Side Effects page.[/FONT]
[h=3]Administration (General):[/h][FONT=&quot]Studies have shown that taking an oral anabolic steroid with food may decrease its bioavailability.[SUP]555[/SUP] This is caused by the fat-soluble nature of steroid hormones, which can allow some of the drug to dissolve with undigested dietary fat, reducing its absorption from the gastrointestinal tract. For maximum utilization, this steroid should be taken on an empty stomach.[/FONT]
[h=3]Administration (Men):[/h][FONT=&quot]The original prescribing guidelines for Nilevar called for a daily dosage of 20 to 30 mg. This was to be administered on an intermittent basis, with the drug taken for no more than 12 consecutive weeks. Thereafter, a break of at least 1 month was advised before therapy was resumed. When used for physique- or performance-enhancing purposes, the drug is also used intermittently, with cycles usually lasting between 6 and 8 weeks in length followed by 6-8 weeks off. A daily dosage of 20 to 40 mg is most common for such applications. This level is typically sufficient for rapid gains in strength and muscle mass (bulk). The high estrogenicity makes norethandrolone of little value in speed and endurance sports, causing an unwanted retention of water weight. When given by injection, the same milligram dosage is recommended as when the drug is given orally.[/FONT]
[h=3]Administration (Women):[/h][FONT=&quot]The original prescribing guidelines for Nilevar made no special dosing recommendations for women, although it did warn that androgenicity is likely on a high dosage. When used by women for physique- or performance-enhancing purposes, a daily dosage of 5-10 mg is most common, taken for no longer than 4 weeks. This level is quite effective for promoting new muscle growth. Note that virilizing side effects are still sometimes noticed at lower doses,and need to be carefully examined for.[/FONT]
[h=3]Availability:[/h][FONT=&quot]Pharmaceutical preparations containing norethandrolone remain scarce, and are rarely diverted for black market sale. The only region of note where this compound is still made is Australia.[/FONT]

 

[Pcushion]

Androgenic 100
Anabolic 100
Standard Testosterone (Standard)
Chemical Names 4-androsten-3-one-17beta-ol, 17beta-hydroxy-androst-4-en-3-one
Estrogenic Activity moderate
Progestational Activity low
​

[h=3]Description:[/h][FONT=&quot]Sustanon 250 is an oil-based injectable testosterone blend that contains four different testosterone esters: testosterone propionate (30 mg); testosterone phenylpropionate (60 mg); testosterone isocaproate (60 mg); and testosterone decanoate (100 mg). Sustanon® is designed to provide a fast yet extended release of testosterone, usually requiring injections once every 3 to 4 weeks in a clinical setting. This is an improvement from standard testosterones such as cypionate or enanthate, which provide a shorter duration of activity. As with all testosterone products, Sustanon 250 is a very strong anabolic drug with pronounced androgenic activity. It is most commonly used in bulking cycles, providing exceptional gains in strength and muscle mass. A shorter-acting version of Sustanon, called Sustanon 100, is also made in certain areas (see:Sustanon 100).[/FONT]
[h=3]History:[/h][FONT=&quot]Sustanon 250 first appeared on international drug markets during the early 1970’s. It was developed by the international pharmaceutical giant Organon (now Merck/MSD), also responsible for such steroids as Durabolin®, Deca-Durabolin®, and Andriol®. Sustanon 250 was designed to offer a therapeutic advantage over existing single esters of testosterone, which need to be injected more frequently (cited advantages in hormone stability are probably not valid). In spite of this advantage, however, Sustanon 250 has never been approved for sale in the United States, although around the world it is one of the most popular brands of testosterone available. The lack of U.S. availability is probably due to the high costs associated with the FDA approval process and the availability of other somewhat comparable agents.[/FONT]
[FONT=&quot]Over the past 25 years, Sustanon 250 has probably been the most sought-after injectable testosterone among athletes. It must be emphasized, however, that this is not due to an unusual potency of this testosterone combination (esters really only affect the release of testosterone). This is simply due to the fact that a stack of four different testosterone compounds is a very good selling point; it is perceived to have more value. In most instances you will actually get a lot more for your money with testosterone enanthate or cypionate. The advantages to be found in Sustanon 250 are for the medical user only. If you were tied to your doctor for regular injections, then Sustanon 250 would allow you to visit him or her less frequently. This equates to a clear improvement in patient comfort. But if you are a bodybuilder injecting the drug every week, blood levels will build to the same extremes with either type of testosterone, and the added expense is probably not warranted.[/FONT]
[h=3]How Supplied:[/h][FONT=&quot]Sustanon 250 is widely available in human and (select) veterinary drug markets. Packaging volume may vary by country and manufacturer; the majority of products are supplied as 1 mL glass ampules.[/FONT]
[h=3]

[/h][h=3]Structural Characteristics:[/h][FONT=&quot]Sustanon 250 contains a mixture of four testosterone compounds, which where modified with the addition of carboxylic acid esters (propionic, propionic phenyl ester, isocaproic, and decanoic acids) at the 17-beta hydroxyl group. Esterified forms of testosterone are less polar than free testosterone, and are absorbed more slowly from the area of injection. Once in the bloodstream, the ester is removed to yield free (active) testosterone. Esterified forms of testosterone are designed to prolong the window of therapeutic effect following administration, allowing for a less frequent injection schedule compared to injections of free (unesterified) steroid. Sustanon 250 is designed to provide a rapid peak in testosterone levels (24-48 hours after injection), and maintain physiological concentrations for approximately 21 days.[SUP]586[/SUP] Each 250 mg ampule provides 176mg of testosterone.[/FONT]
[FONT=&quot][/FONT]

[FONT=&quot]Figure 1. Serum testosterone levels after a single injection of Sustanon 250. Source: Clinical Endocrinology (1984) 21, 97-107[/FONT]​

[h=3]Side Effects (Estrogenic):[/h][FONT=&quot]Testosterone is readily aromatized in the body to estradiol (estrogen). The aromatase (estrogen synthetase) enzyme is responsible for this metabolism of testosterone. Elevated estrogen levels can cause side effects such as increased water retention, body fat gain, and gynecomastia. Testosterone is considered a moderately estrogenic steroid. An anti-estrogen such as clomiphene citrate or tamoxifen citrate may be necessary to prevent estrogenic side effects. One may alternately use an aromatase inhibitor like Arimidex® (anastrozole), which more efficiently controls estrogen by preventing its synthesis. Aromatase inhibitors can be quite expensive in comparison to anti-estrogens, however, and may also have negative effects on blood lipids.[/FONT]
[FONT=&quot]Estrogenic side effects will occur in a dose-dependant manner, with higher doses (above normal therapeutic levels) of Sustanon 250 more likely to require the concurrent use of an anti-estrogen or aromatase inhibitor. Since water retention and loss of muscle definition are common with higher doses of testosterone, this drug is usually considered a poor choice for dieting or cutting phases of training. Its moderate estrogenicity makes it more ideal for bulking phases, where the added water retention will support raw strength and muscle size, and help foster a stronger anabolic environment.[/FONT]
[h=3]Side Effects (Androgenic):[/h][FONT=&quot]Testosterone is the primary male androgen, responsible for maintaining secondary male sexual characteristics. Elevated levels of testosterone are likely to produce androgenic side effects including oily skin, acne, and body/facial hair growth. Men with a genetic predisposition for hair loss (androgenetic alopecia) may notice accelerated male pattern balding. Those concerned about hair loss may find a more comfortable option in nandrolone decanoate, which is a comparably less androgenic steroid. Women are warned of the potential virilizing effects of anabolic/androgenic steroids, especially with a strong androgen such as testosterone. These may include deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement.[/FONT]
[FONT=&quot]In androgen-responsive target tissues such as the skin, scalp, and prostate, the high relative androgenicity of testosterone is dependant on its reduction to dihydrotestosterone (DHT). The 5-alpha reductase enzyme is responsible for this metabolism of testosterone. The concurrent use of a 5-alpha reductase inhibitor such as finasteride or dutasteride will interfere with site-specific potentiation of testosterone action, lowering the tendency of testosterone drugs to produce androgenic side effects. It is important to remember that anabolic and androgenic effects are both mediated via the cytosolic androgen receptor. Complete separation of testosterone’s anabolic and androgenic properties is not possible, even with total 5-alpha reductase inhibition.[/FONT]
[h=3]Side Effects (Hepatotoxicity):[/h][FONT=&quot]Testosterone does not have hepatotoxic effects; liver toxicity is unlikely. One study examined the potential for hepatotoxicity with high doses of testosterone by administering 400 mg of the hormone per day (2,800 mg per week) to a group of male subjects. The steroid was taken orally so that higher peak concentrations would be reached in hepatic tissues compared to intramuscular injections. The hormone was given daily for 20 days, and produced no significant changes in liver enzyme values including serum albumin, bilirubin, alanine-amino-transferase, and alkaline phosphatases.[SUP]587[/SUP][/FONT]
[h=3]Side Effects (Cardiovascular):[/h][FONT=&quot]Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.[/FONT]
[FONT=&quot]Testosterone tends to have a much less dramatic impact on cardiovascular risk factors than synthetic steroids. This is due in part to its openness to metabolism by the liver, which allows it to have less effect on the hepatic management of cholesterol. The aromatization of testosterone to estradiol also helps to mitigate the negative effects of androgens on serum lipids. In one study, 280 mg per week of testosterone ester (enanthate) had a slight but not statistically significant effect on HDL cholesterol after 12 weeks, but when taken with an aromatase inhibitor a strong (25%) decrease was seen.[SUP]588[/SUP] Studies using 300 mg of testosterone ester (enanthate) per week for 20 weeks without an aromatase inhibitor demonstrated only a 13% decrease in HDL cholesterol, while at 600 mg the reduction reached 21%.[SUP]589[/SUP] The negative impact of aromatase inhibition should be taken into consideration before such drug is added to testosterone therapy.[/FONT]
[FONT=&quot]Due to the positive influence of estrogen on serum lipids, tamoxifen citrate or clomiphene citrate are preferred to aromatase inhibitors for those concerned with cardiovascular health, as they offer a partial estrogenic effect in the liver. This allows them to potentially improve lipid profiles and offset some of the negative effects of androgens. With doses of 600 mg or less of testosterone per week, the impact on lipid profile tends to be noticeable but not dramatic, making an anti-estrogen (for cardioprotective purposes) perhaps unnecessary. Doses of 600 mg or less per week have also failed to produce statistically significant changes in LDL/VLDL cholesterol, triglycerides, apolipoprotein B/C-III, C-reactive protein, and insulin sensitivity, all indicating a relatively weak impact on cardiovascular risk factors.[SUP]590[/SUP] When used in moderate doses, injectable testosterone esters are usually considered to be the safest of all anabolic/androgenic steroids.[/FONT]
[FONT=&quot]To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.[/FONT]
[h=3]Side Effects (Testosterone Suppression):[/h][FONT=&quot]All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Testosterone is the primary male androgen, and offers strong negative feedback on endogenous testosterone production.Testosterone-based drugs will, likewise, have a strong effect on the hypothalamic regulation of natural steroid hormones. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.[/FONT]
[FONT=&quot]The above side effects are not inclusive. For more detailed discussion of potential side effects, see the Steroid Side Effects section of this book.[/FONT]
[h=3]Administration (General):[/h][FONT=&quot]Testosterone propionate is often regarded as a painful injection. This is due to the very short carbon chain of the propionic acid ester, which can be irritating to tissues at the site of injection. Many sensitive individuals choose to stay away from this steroid completely, their bodies reacting with a pronounced soreness and low-grade fever that may last for a few days after each injection.[/FONT]
[h=3]Administration (Men):[/h][FONT=&quot]To treat androgen insufficiency, the prescribing guidelines for Sustanon® 250 call for a dosage of 250 mg every 3 weeks. Although active in the body for a longer time, Sustanon 250 is usually injected every 7 to 10 days for muscle-building purposes. This schedule will allow for the higher doses most commonly applied by athletes, and more stable elevations in hormone level. The usual dosage among male athletes is in the range of 250-750 mg per injection, taken in cycles 6 to 12 weeks in length. This level is sufficient for most users to notice exceptional gains in muscle size and strength.[/FONT]
[FONT=&quot]Sustanon 250 is usually incorporated into bulking phases of training, when added water retention will be of little consequence, the user more concerned with raw mass than definition. Some do incorporate this drug into cutting cycles as well, but typically in lower doses (125- 250 mg every 7-10 days) and/or when accompanied by an aromatase inhibitor to keep estrogen levels under control. Sustanon 250 is a very effective anabolic drug, and is often used alone with great benefit. Some, however, find a need to stack it with other anabolic/androgenic steroids for a stronger effect, in which case an additional 200-400 mg per week of boldenone undecylenate, methenolone enanthate, or nandrolone decanoate should provide substantial results with no significant hepatotoxicity. Testosterone is ultimately very versatile, and can be combined with many other anabolic/androgenic steroids to tailor the desired effect.[/FONT]
[FONT=&quot]Some bodybuilders have been known to use excessively high dosages of this drug (1,000 mg per week or more), although this practice is generally not advised. At dosages above 750 mg per week, water retention will likely account for more of the additional weight gain than new muscle tissue. The practice of “megadosing” is inefficient (not to mention potentially dangerous), especially when we take into account the typical high cost of Sustanon 250. Such use is usually not justified outside of aggressive bodybuilding regimens.[/FONT]
[h=3]Administration (Women):[/h][FONT=&quot]Sustanon 250 is rarely used with women in clinical medicine. When applied, it is most often used to induce masculinization in female to male transsexuals. Sustanon 250 is not recommended for women for physique- or performance-enhancing purposes due to its strong androgenic nature, tendency to produce virilizing side effects, and slow-acting characteristics (making blood levels difficult to control).[/FONT]
[h=3]Availability:[/h][FONT=&quot]Sustanon remains a popular testosterone product in many countries outside of the United States. The vast majority of products in western markets are made by or under license from Organon (now Merck/MSD), though many “clone” products are also manufactured in less regulated markets of Asia.[/FONT]

 

[Oldman85]

Test is Best. It just is.